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INTRODUCTION 
Well being of humans are not designed in heaven but by us and the atmosphere 
around us.  Dramatic life style modifications have introduced lots of harmful effects in 
the form disease to the society. Health of an individual not only depends on his physical 
state but also on his Mental state. To make the body and the mind in perfect shape, 
people are in a quest for a natural remedy which will be rendered by our traditional 
system. The medicines used in siddha system are prepared from Herbals, Minerals and 
Animals which will not cause any side affects on proper usage. In the materialized 
world, people have started to look back at their traditional science in which the natural 
atmosphere dwell.  
   One such traditional system is Siddha system of medicine which is one of the 
oldest traditional system in the world.  It is a system which not only deals with the 
physical health but also induces changes in the soul of an individual.  Our siddha system 
stabilizes the mind and improves the well being of the people. Nowadays not only the 
body of the human being gets affected by disease but also the Mind due to various 
activates being followed. So it is very obvious that the society is looking for system 
which provides holistic approach for curing disease and it will be provided by our siddha 
system Siddha system of  medicine, which was preferred and practiced by Siddhar’s, 
who are the forerunners of indigenous medical science.  The siddhar’s are persons who 
practiced Meditations, pranayamas and other Yogic practices, so that they  have attained 
Siddhi and super natural powers, and also  to cure the sufferings. They discovered many 
natural medicines which are widely used for treating many disease. 
 According to Siddha system of medicine, Health is defined as the state of 
physical, psychological, Social and Spiritual component of a human being.  All the 
objects in this world either living or non-living are composed of five elements (Pancha 
Bootham) namely; Earth - Man, Water   - Neer, Fire – Thee, Air  - Kaatru , Ether  - 
Aagayam.  Physical health of human body is maintained by the three basic vital forces 
(humours) namely Vaatham, Pitham, Kabam called Uyirthathukal which are activated by 
the function of Panchabootham (Five elements). When the above humours are affected 
or not in a balanced state they become Kutrams which then disposes to diseases. In 
Siddha system the diseases are classified according to Mukkutram theory and diseases 
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are 4448 in numbers. The Vaatham diseases are 80, Pitham diseases 40 and Kabam 20 in 
number.  Siddhar yugi munivar has classified Vaatha disease into 80 types. 
 In human beings the life stages are classified as  Pre natal,  Newborn, infants, 
Early childhood, Middle childhood, late childhood and adolescent, Early adult hood, 
Midlife, Mature adult, Late adult hood and Death.   In between these 12 stages of the life 
the human body will be affected by disease. According to the siddha system the pediatric 
life stages are classified into10 stages. They are Kaapu paruvam (0-3Months), sengeerai  
(3-5 months) Thaal (5-7months), sappani (7-9months), mutham (9-11months), varugai  
(11-13months), ambulli (13-15months) these 7 stages are common for male and female 
child. After this period siruparai (15-17months), sitril (17-19Months), siruther  
(19-21months) are mentioned for male children and kazhangu (15-17months), ammanai 
(17-19Months), oosal (19-21months) are mentioned for female children. There are many 
diseases commonly affecting the children from the  time of conception to Adolescence.  
One among them is ―Baala Vaatham” which is mainly interfering with the principal 
function of locomotion in human being.  In this disease commonly Nervous system is 
being involved and in later stages it make discomfort, disability and inability to the 
individual.  This disease is also mentioned in siddha pediatric text books. Hence the 
author is interested to try an effective remedy to the suffering children and evaluvate this 
disease also with the modern aspect with the application of basic principles of Siddha 
and also with the supporting modern parameters. The sage Agasthiyar has classified 
Baala Vaatham into 8 types in his book of ―Agasthiyar Kummi‖  
―Physically challenged children‖ is a blanket term used to classify conditions that 
childhood disability caused by neuronal damage .The proportion of disabled children in 
developing countries is generally higher than in developed countries, it is estimated that 
6% to 10% of children in India are born disabled.  Developmental disabilities are some 
of the most upsetting for a family to deal. Diagnosis like cerebral palsy, Autism, Down 
syndrome, ADHD and intellectual disabilities often cause children to be removed from 
the mainstream, and parents must be brutal advocates to make sure their children receive 
the services, therapy, and inclusion they need and deserve. At present, no health care 
profession has convincingly assumed the responsibility of the health for physically 
challenged children. Although drug therapy may not completely correct complications 
associated with childhood disability, evidence does show that it helps in managing  
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problems. There are many physical disabilities that can affect children. In our siddha 
paediatric text, the definition for Baala Vaatham has been given as: 
1 
 thiynad;w Foe;ijf;F thjk; te;jhy; 
  trk;nfl;L iffhYk; tpsq;fplhJ 
Nfhynkd;w rf;jpaJ Fiwe;J fhZk; 
  Fioe;J tpOk; euk;ngy;yhk; jsh;e;J epw;f;Fk; 
fhynkd;w fhy; fuKk; apl;lh Nghyhk; 
  fz;lj;jpy; tpir jsUk; fOj;J NfhZk; 
rPykpf elf;f xl;lh rPjk; Njhd;Wk; 
Njfj;jpy; Fsph;r;irAz;lhk; tpiwf;Fk; jhNd. 
 
In the pediatric text book of  Mathalai Noi thokuthi part 3, the symptoms of  
Baala Vaatham is explained as inability/ difficulty to use the limb, loss of power and 
tone, nerve weakness, inability to move the affected limb, deviation, loss of energy, 
weakness, chills, spasticity of the affected part.   
The symptoms of Baala vatham may be related with Paresis. Paresis means 
weakness. It is the condition typified by a weakness of voluntary movement or partial 
loss of voluntary movement or by impaired movement. It mainly affects both upper 
limbs and lower limbs. It affects both sex. Most of the children have spastic paresis.  
Health and lifestyle early in life been have profound impact on health and quality of life 
in recent year.  The prevalence of paresis range is 50% to 80% hospital based reported in 
world wide.  Mostly upper limb weakness is marked in 77% of patients and lower limb 
weakness in 72%. The incidence rate of paresis in India is currently estimated to be 
approximately 1.5 million new cases reported in 2010. This is a staggering number, 
every minute,  7 people will acquire a neurologic disability, amounting to nearly 11,000 
every day. (NCBI Neurology. 2012 Nov 20).  Presently, Supportive therapies for training 
the children with PARESIS like  physio therapy, occupational therapy,  Psycho therapy 
etc… are being used. Certain medication like Antispastic drugs are also used in severe 
condition. Still now its quite challenging to manage the children with PARESIS with 
existing therapy.  
In NIS many more Paresis children are  reporting to our Kuzhanthai Maruthuvam 
Department. In the Siddha system of medicine, herbs, minerals, metals and salts are have 
been used for preparing the medicine.  However, scientific research, using modern 
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techniques is needed to provide additional evidence on the drug standardization. In this 
context, the need exists to evaluate  many Siddha drugs and therapies in contemporary 
use, which also includes Mind–body interventions, Biological based therapies such as 
formulations and diets, Manipulative  methods such as Thokkanam.  Thus the aim and 
objectives of the present study was to test the efficacy of the Siddha   medicines / 
methodologies in PARESIS children. The purpose of this project is to develop 
recommendations on ―best practices‖ related primarily to the evaluate Siddha 
methodologies and Medicines. Different treatment modalities can improve the quality of 
physically challenged children and these can include internal medication and External 
therapies like Thokkanam (Massage). Because children with PARESIS have multiple 
symptoms for which no curative treatment exists, their families seek therapies from 
many sources. Some look for cures, while others seek therapies that will improve the 
way of their children day to day activites. None of the siddha medicines/methodologies 
used to treat spasticity in children has been adequately tested for safety and efficacy.  In 
this regard, it was decided to take up a combination of Siddha formulation and therapy 
for the study. The drugs chosen for the  project included CHITRA MUTTI KUDINEER 
as internal medicine, BAALAVAATHA THYLAM as External for thokkanam, all of 
which have been used in the Siddha system of medicine for many centuries either singly 
or in various combination. In order to limit this issue, efforts were undertaken to study 
the result of the use of a combination of these therapy. 
  These drugs are also mentioned in siddha  text books.  The  Internal drug Chitra 
Mutti Kudineer Chooranam is a herbal preparation mentioned in the text book of 
―Tharala mani pala Vaagadam‖.   Most of the raw drugs in Baala Vaatha thylam which is 
used for external application  have Anti- Vaatha , Tonic, Stimulatn, Neuroprotective, 
property  mentioned in the text book of ―Mathali Noi Thoguthi‖  other than the internal 
and external medications used in siddha system, an unique art in the name of Thokkanam 
has been gifted to the community by siddhars.  Stimulation of blood circulation and the 
nervous system in the body cures disease pertaining to the muscles tendon, ligaments, 
bones and nervous and internal organs.  In this study , apart from internal and External 
medicines, the effect of thokkanam  is also be assessed. 
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AIM AND OBJECTIVES 
AIM: 
 To Evaluate the therapeutic efficacy of siddha drug ―Chitra Mutti Kudineer‖  
(Internal) and ―Baala Vaatham‖  (External) in the treatment of Baala Vaatham (Paresis) 
by clinical assessment with siddha therapeutic management in children. 
 
OBJECTIVES: 
 To Calibrate the Resemblance and the Equivalence of Baala vatham with Paresis 
 To  correlate the   Siddha and modern aspect of the disease 
 To evaluate the Bio-chemical, Phytochemical, physicochemical  and Safety of the 
trial drug ―Chitramuttikudineer‖ (Interal) 
 To establish the treatment for Baala Vatham with the siddha medicine 
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SIDDHA ASPECT 
BAALA VAATHAM 
The main cause for the disease Baala Vaatham due to the deragment in vaatham.                                          
Siddha system of Medicine is an ancient one enriched with good resources. The sources 
of Siddha medicines include Herbs, Minerals, Metals and also animal origin. 
 Siddha system was propounded by the Siddhars is a vast and unique system 
which defines health as a perfect state of physical, psychosocial, social and spiritual 
wellbeing of an individual.  
 The system not only deals with medicinal but with spirituality, righteous way of 
living, Rejuvenation and its main aim is attainment of perfection. 
'mz;lj;jpYs;sNj gpz;lk; 
gpz;lj;jpYs;sNj mz;lk; 
mz;lKk; gpz;lKk; xd;Nw  
mwpe;Jjhd; ghh;ifapNy' 
rl;lKdp Qhdk;. 
 
  The universe around as in the Macrocosm (Andam) and the human body is 
considered as the Microcosm (Pindam). Any changes in the Macrocosm will have its 
impact in the Microcosm in the human body.  
epye;jP ePh;tsp tpRk;Ngh ile;Jk; 
  fye;j kaf;fk; cyfk; Mjypd; 
,Ujpid Ik;ghy; ,andwp toh mikj; 
jphptpy; nrhy;nyhL jhoMy; Ntz;Lk; 2 
-njhy;fhg;gpak; nghUs; mfuhjp 
 
The poet explains that both Andam and Pindam formed by the basic five 
elements called panchaboodhams.  They are   
1. Pirithivi (Earth)   
2. Appu (Water)   
3. Theyu (Fire)  
           4. Vaayu (Air)   
5. Aahayam (Ether)  
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These five elements combined to form Three Thathus.   
1. Vaatham  
2. Pitham   
3. Kabam 
 
These three thathu  composed of   
1. Vatham  = Air + Earth 
2. Pitham   = Fire  
3. Kabam   = Earth + water  
 
The physiological units of the Human body is otherwise called as Vali (Vatham), 
Azhal (Pitham) and Iyyam (Kabam).  They are also formed by the combination of the 
five basic elements.  Accordingly Vali is formed by the combination of Vayu (Air) and 
Aagayam (Space). This is the Creative force. Azhal is formed by theyu (Fire). This is the 
Force of  Preservation.  Iyyam is formed by Prithivi (Earth) and Appu (Water).  This is 
the Force of Protection.  These three humors are in the ratio of 4:2:1 in equilibrium 
which is a healthy normal condition and disturbance in their equilibrium leads to 
diseases. This is denoted in 
 
 ―nghq;fpa ije;Jf;Fs; nghy;yhjJ ,k;%d;Wjhd; 
jq;fpa thA rkj;jd; kfhthjk; 
gq;fpa td;dpahy; gFe;jJ gpj;jNk 
gFe;j ryj;jpy; ghprpf;Fk; ey;iyAk; 
tFe;j ,k;%d;why; tsh;e;jJ Nehnay;yhk; 
mFe;jJ jhdwpe;J mstpl;l Nahfpfs; 
kfpo;e;Nj apjpapy; epd;wkaf;fk; mwpthNw 
-gjpnzd; rpj;jh; ehb rh];j;jpuk;. 
Mode of Action: 
Actually it is invisible. It can be professed through its movements in our body. 
Locations: 
Below the umbilicus. 
  
―ehnkd;w  thjj;Jf; fpUg;gplNk Nfsha; 
  ehgp;f;Ff; fPnOd;W etpy yhFk;‖ 3 
-a+fpKdp  
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As per yugi muni, ―Vatham‖ lies in, 
1. Abanan 
2. Edakalai 
3. Kamakodi 
4. Undhiyini keezh moolam 
5. Hip region  
6. Bones 
7. Muscles 
8. Nerves 
9. Joints 
10. Skin 
11. Hair follicles 
12. Stools 
It also lives in the Gastro intestinal tract, Bones, Ear Thigh, Hip and skin. 
Properties of Vaatham
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1. Giving briskness 
2. Expiration and inspiration 
3. Functioning of the mind, thoughts and body 
4. Regulation of the ―fourteen Physiological Reflexes‖ (Vegam) 
5. Functioning of the ―Seven Udal Kattukal‖ uniformly 
6. Protection and strengthening of the five sensory organs. (Iymporigal) 
Charecteristics of Vaatham: 
1. Body ache 
2.  Pricking pain 
3. Tearing pain 
4. Nerve weakness 
5. Mental distress 
6. Movements 
7. Pain in the joints 
8. Traumatic pain 
9. Dislocation of joints 
10. Weakness of organs 
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11.  Paralysis of the limbs 
12. Polydypsia 
13. Severe pain in calf and thigh muscles 
14. Bony pricking pain 
15. Anuria and constipation 
16. Unable to do flexion and extension of the limbs 
17. All tastes like astringent 
18. Excess salivation 
Natural qualities of Vatham: 
1. Kadinam  -  Roughness 
2. Varatchi  -  Dryness 
3. Elesu  -  Lighter 
4. Kulirichi  -  Coldness 
5. Asaithal  -   Unstableness 
6. Anuthuvam -   Subtleness 
Opposite Qualities of Vatham: 
1. Mirudhu  -  Softness 
2. Pasumai  -  unctuous 
3. Paluvu  -  Heaviness 
4. Akkini  -  Hot 
5. Sthirm  -  Stableness 
6. Katti  -  solidity 
Diet: 
njhopy;ngW ifg;Gf;fhh;j;jy; Jth;j;jy; tpQ;RfpDQ; 
 NrhWk; fioajhk; tuF kw;iwg;ige;jpid aUe;jpdhYk; 
 Vopy; ngwg; gfYwq;fp ,utpdpYwq; fhjjhYk;    
 kio epfu; FoypdhNy thjq;Nfh gpf;Fq; fhNz. 
-guuhr Nrfuk; 
 
 Intake of bitter, astringent and pungent taste in excess, consumption of cold 
foods, intake of millet etc., aggravate vatham. 
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Kj;Njhlq;fis kpFjpg; gLj;Jk; Ritfs;: 
―GspJth;tpQ; Rq;fwpahw;g+Hpf;Fk; thjk; 
 XspAth;ifg; Ngwpy; gpj; Jr; rPWk; --fpspnkhopNa 
 fhh;g;gpdpg;G tpQ;rpw; fgk;tpQ;RQ; rl;bujr; 
 Nrug;Gzh; NehaZfhNj‖. 4 
 
 The tastes, which increase Vatham are sour and Astringent. 
 
Kj;Njhl kpFjpia rkdQ; nra;Ak; Ritfs:;  
―thj Nkypl;;lhy; kJuk; GspAg;G 
NrjKwr; nra;AQ; rpiwak; -- Xjf;Nfs; 
fhue; Jth;frg;Gf; fhl;LQ; Ritnay;yhk; 
rhug; ghpfhuQ; rhw;W‖ 5 
-(fz;Zrhkpak;) 
 
The tastes, which neturalizes vatham are sweet, sour and salt. 
 
Precipitating factors: 
Ehnyd;wthjk; te;j tifjhNdJ 
 Ez;ikaha;f; fd;kj;jpd; tifiaf; NfS 
fhypNy Njhd;wpaJ fLg;gNjJ 
 iffhypy; Klf;fpaJ tPf;fNkJ 
NfhypNy gLf;fpd;w; tpUl;rkhd 
 Foe;ijkue; jid ntl;ly; Nky; Njhy; rPty; 
ehtpNu rPt nre;J fhy; Kwpj;jy; 
 ey;ynfhk;G jio Kwpj;jy; eypj;jy; fhNz.7 
      - mfj;jpah; fd;k fhz;lk;  
 
kanmavinai (sins commited in the previous birth)  
Habits: 
ntapypy; elf;ifahYk; kpfj;jz;zPh; Fbf;ifahYk; 
nra;apio kfspio Nrhh;e;jDg tpf;ifahYk;  
igaNd cz;ikahYk; ghfw;fha; jpz;ifahYk;  
 ijaNay thjNuhfk; rdpf;Fnkd; wwpe;J nfhs;Ns8 
-Njiuah; thflk;  
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Walking in hot sun, excessive intake of water, intake of bitter gourd may 
predispose to vatha disease. 
Environmental factors: 
thjth;j; jidfhy NkNjh ntd;dpy; 
  kUTfpd;w thdpfh; flf khFk; 
 Mjiyg; grpNahL fhh;j;jpif jd;dpy; 
  mlUNk kw;wkh jq;fs; jd;dpy; 
 NghjNt rkpf;Ffpd;w fhy khFk9 
-A+fp itj;jpa rpe;jhkzp  
 
 Vatha disease will be precipitated during the month from aani to kaarthigai (June 
to December). 
thjk; kpFjpahFk; fhyq;fs;: 
gJkj;ij G+f;fitf;Fk; ghDkpff; fhAk; 
 KJNtdp ypw;GtpePh; Kw;Wk; - fJnkd 
 tw;Wk; fgk/Fk; thAkpFk; tho;khe;jh;;f; 
 Fw;w eypf; Nfjpnjd; NwhJ.10 
 
In muthuvenil kaalam, the increased solar radiation increases the evaporation of 
the water content in the world.  At the same time, the similar action on the body produces 
increased absorbtion of water from mucosa for digestion and develops the vitality of 
vatha disease.  So this disease occurs predominatly in muthuvenil kalam. 
Pathophysiology: 
 Change in lifestyle, occupation, food and habits lead to development of this 
disease by causing derangement of macro elements in the body (pancha boothangal). 
 Improper food habits alter the elemental composition directly while the other 
causes lead to derangement of these elements indirectly.  When the elemental 
composition is altered uyir thaathukkal or the three humors which are made up of these 
elements naturally get deranged.  This simultaneously leads to derangement of seven 
udal thaathukkal, which produces symptoms of baalavatham. 
 
 12  
ghy thjk;  
thiynad;w Foe;ijf;F thjk; te;jhy; 
trk;nfl;L iffhYk; tpsq;fplhJ 
Nfhynkd;w rf;jpaJ Fiwe;J fhZk; 
Fioe;J tpOk; euk;ngy;yhk; jsh;e;J epw;f;Fk; 
fhynkd;w fhy; fuKk; apl;lh Nghyhk; 
fz;lj;jpy; tpir jsUk; fOj;J NfhZk; 
rPykpf elf;f xl;lh rPjk; Njhd;Wk; 
Njfj;jpy; Fsph;r;irAz;lhk; tpiwf;Fk; jhNd.1 
-kjiyNeha; njhFjp  
 
ghy thj cw;gj;jp tpguk; 
 
nrhy;ypa ghythjk;; njhlh;e;jpLk; tpguq;NfS 
nky;ypa fUtpy; te;J Nktpa jpir thATfs; 
ey;ypaypy;yhky;j; jhd; ehjKQ; NrUkhfpy; 
jy;ypa FzKk; tp;l;Ljiwe;jpLk; euk;GjhNd.11 
      -ghy thj epjhdk;. 
 
Foe;ijfSf;F ghythjk; Vw;gLk; fhuzj;ijk; fUthdJ cw;gj;jp MFk; 
NghJ RNuhzpjj;Jld; gj;Jtif thAf;fSk; Nrh;e;J Fzq;fSf;F Vw;g 
euk;GfSf;F Vw;g euk;Gfisg; gw;Wk;. 
 
je;ijAk; jhAk; $b jOtpNa Gzh;e;j ehspy;  
te;JKd; nra;j; Njh\kUtpNa fh;g;gf; $l;by;  
tpe;jpahfp ruj;jpDhNl Ntq;FONyhlk; NghNy 
me;j ehs; cWg;igj; njhl;L mlh;;e;jpLk vd;;W vz;zyhNk.11 
      -ghy thj epjhdk;. 
 
NkYk; jha;> je;ijah;fs; clYwT nfhs;Sk; NghJ fUtpy; ,izAk; 
Mj;kh> Kd; nrd;kj;jpy; nra;j fUkq;;fsp;;d; gyhgyd;fs;gb> fh;;g;gj;jpNyNa 
Neha; mjd; cWg;Gfspy; Fbf;nfhs;Sk.;  
 
mlh;e;jpLk; rlj;jpNyjhd; mf;fpdp fzf;fpy; ep;d;W  
Jlh;e;Jjhd;Fiwe;Jk; kPwp RfKw;W Fsph;r;irahfpy; 
clde;j fh;g;ge;jdpy; cUtpNa akh;e;j Nehf;fk;  
ele;JNk ehw;gj;J ehy;khjk; - tU\j;jpd; NkNy11 
       ghy thj epjhdk;.  
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clypy; #lhdJ gutp njhlh;;e;J epd;W $bAk; Fiwe;Jk; rpy 
Ntisfspy; Fsph;;e;Jk; ,Uf;Fk;.  ,e;epiy fh;;;gg;igapypUf;Fk; Foe;ijia 
ghjpf;Fk;.  Foe;ij gpwe;j ehw;gj;jp ehd;F khjq;fSf;fg; gpwF thj Nehahf 
khWk;. 
 
Nky; jhtpaJ vd;W kpFe;jpLj; %d;W Ie;Jk; 
Fhykhkjdpd; NkYk; fz;bLkPuhw; kl;Lk; 
rPykha; te;J thjk; rpRf;fSf;F JlUnkd;W 
rhyNt Kdptdp jhDk; ghyw;; nfd;Nw.11 
      ghy thj epjhdk;.  
 
NkYk; %d;W> Ie;J> gd;dpnuz;L> tUlq;fspy; thjkhdJ Foe;ijfis 
njhlUk;; vd;W Ntjq;fs; XJk; Kdpth;fs; nrhy;ypAs;sdh;.  
  
vd;wNjhh; Kd; nrd;kj;jpd; ,ire;Jld; ,th;fs; jhDk; 
epd;wNjhh; rPtnre;J epiy jsh;;e;jpLj; thw; jd;id 
nfhd;wplhJ ijj;J if fhy;fisJiyj; jpl;l ghtj;jhYk; 
md;W jhd; nghpNahh;rhkprf;jpfs; tzq;fhjjhYk; 11 
ghy thj epjhdk;.  
       
Kw;gpwtpapy; caph; gpuhzpfis epiy jsUk; tz;zk; cijj;J if> 
fhy;fis Kwpj;J tpl;l ghtj;jhYk;> nghpath;fs; ,iwtd; ,th;fis 
tzq;fhjjhYk;> 
 
tzq;fhj Nfhgj;jhy; rhgj;jhYk; 
  ty;tpidahk; jPtpidfs; mjpfj;jhYk; 
,zq;fhj Nfhgj;jhy; mOifahYk; 
  ,iuajdhy; kyryj;jpd; nge;jj;jhYk; 
fzq; fhy;if euk;gpyhdJ Cdj;jhYk; 
fzj;jgpyd; nra;jjhYk; thjk; te;J 
 tzq;fhNj ahDNk ,J thiyfSf;F11 
ghy thj epjhdk;.  
 
Nfhgj;jhYk;> rhgj;jhYk;> jP tpidapd; gydhYk;> mOifahYk;> 
cz;Zk; cztpYs;s Fw;wj;jhYk;> kyk;> rpWePh; ,itfis fl;LtjhYk;> if> 
fhy; euk;Gfspd; Cdj;jhYk;> cliy ,Wf;fpg; gpbg;gjhYk;> Foe;ijfSf;F 
thjk; te;J NrUk;. 
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$WNtd; ,jpy; vl;Ltifapd; NgUk; 
  Fwpg;ghf rhj;jpaKk; mrhj;jpae;jhDk; 
NtWNk mT\jKk; fpwpifahTk;  
  tpgukjha; jpfOk; fopg;Gk; nra;a 
MWNk tpirjsh;e;J NehTk; khwp 
  mq;fkJ ed;whfp tsh;;e;J Nky; Nky; 
NjWNk cly; gyj;J jplkhf 
  jpUe;jpLthnud;W Kdp nrhd;dkhNk.11 
-ghy thj epjhdk;.  
 
Foe;ijfSf;F tUk; vl;L tif thjj;jpd; ngaUk;> rhj;jpa mrhj;jpag; 
gphpTfisAk;> kUe;J tiffisAk;> fphpif> fopg;G Kiwfs; Nghd;wtw;iw 
nra;jhy; thjj;jpd; tpir jsh;e;J NtjidAk; ePq;fp cly; jplKld; 
nrk;ikaha; tsh;e;J tUnkd;W khKdp $wpa mUk; fUj;jhFk;. 
 
 ghy thjk; vl;Lf;Fk; ngah; 
Mnkd;w Ruj;jpd; thjk; mf;fpdp thjj;NjhNl 
Xnkd;w Kythjk; czf;fpa thje;jhDk; 
jhnkd;w mjprhuthjk; jWf;Fk; Nky; %r;Rthjk; 
Nghnkd;w tpiuapy; thjk; nghUj;Jthjq;fnsd;Nw.11  
- ghy thj epjhdk;.  
 
Ruj;jpd; thjk>;; mf;fpdp thjk;> %ythjk>; czf;fy; thjk;> mjprhuthjk;> 
Nky; %r;Rthjk>; tpiuthjk;> nghUj;J thjk; MfpaitNa MFk;. 
 
rhj;jpak; mrhj;jpak; 
 
vl;L thjq;fs; jd;dpymirTWk; rhj;jparhj;jpak; 
kl;;lkhQ; Ruj;jpd; thjkpire;j mf;fpdpapd; thjk; 
tpl;lW %ythjk; tpiuapdpy; thjk; ehYk; 
lkhjPUQ; rhj;jpak; jPuhJ czf;fy; thjnkd;Nw11 
        - ghy thj epjhdk;.  
 
Kd; nrhd;d vl;Ltif thjq;fspd; Ruthjk;> mf;fpdp thjk>; %ythjk; 
tpiuthjk;> Mfpa ehd;F tpj thjq;fs; rhj;jpag; gphpitr; rhh;;e;jJ. 
 
thjNk nghUj;J thjk; tUFk; Nky; %r;R thjk; 
rPjNk mjprhuj;jpd; nrg;gpa thjk; ehYk; 
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Nfhjw jPh;e;jplhJ nfhLk; gpzp mrhj;jpakhFk; 
jPjwg; nghjpif thOk; jpU Kdp mUspr; nra;jhh11; 
        - ghy thj epjhdk;.  
 
czf;fy; thjk;> nghUj;J thjk>; Nky; %r;R thjk;> mjprhuthjk;> Mfpa 
ehd;F tpj thjq;fSk; mrhj;jpag; gphpit rhh;;e;jnjd;W nghjpif kiyapy; 
thOk; mfj;jpa Kdpth; jPh;;f;fkha; $wpAs;shh;. 
Ruthj Fzk;  
 
Fj;jpLk; mq;fnky;yhk; nfhLk; Ruk; Nfhgkhfp 
Rw;wpLKjph;Jd;id Rod;WNly; the;jpAz;lhk; 
,tw;wptyk; tp;;lhJ ,Lg;nghU gf;fk; jd;dpy; 
tw;wpa ghyw;nka;apy; tUk; Ruthje;jhNd.11 
 
cly; KOtJk; Fj;jYk>; RuKk; Vw;gl;L> mjd; tpisthf 
the;jpAz;;lhFk;> kyk; rhpahf ntspahfhJ> ,Lg;gpd; xU gf;fk; Nja;;e;J tUk;  
,ij Ruthjk; vd;gh;. 
 
mf;fpdp thjj;jpd; Fzk; 
 
vhpj;jpLk; Njfnky;yhk; ,UkYk; nrUkYz;lhk; 
ngUe;jpLk; rpuq;Fk; cz;lhFk; Nga; KspKspf;Fk; gps;is 
mhpj;jpLk; Klq;Fk; if fhy; md;id ghy; cz;z khl;lhh; 
njhp;e;jpLk; mhpg;GKz;lhFk; rpy;nyhp rj;jhkhNk mwp.11 
 
cly; KOtJk; vhpr;ry; vOk;> ,Uky;> nrUky; Vw;gLk; rpuq;Fk; 
cz;lhFk;. Foe;ij Nga;Kop Nghd;w gaq;fukhdg; ghh;itiaf; fhl;Lk;.  
clypy; mhpg;Gj; Njhd;Wk;> if fhy;fis Klkhf;Fk;> jha;g;ghy; Fbf;f khl;lhJ 
FuyhdJ rpy;nyhp tz;bd; rj;jk; Nghy; Njhd;Wk;> ,JNt mf;fpdp thjf; 
Fzq;fshFk;. 
 
%ythj Fzk;  
tUkby; FopypdhNsh ike;jh;Nky; jpkpw;G cz;lhFk; 
nghUkYk; kyk; tplhJ Gf;fpLk; Mfe;jd;dpyl 
nrUkYk; Nth;itahfp NruNt FSe;J fhl;Lk; 
tpUtpNa vl;lhk; ehspy; tpl;bl fhypy; NrhUk11; 
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%ythjk; Vw;gl;l Foe;ijapd; clypy; jpkph;g;G Vw;gLk;. tapw;wpy; 
nghUky; cz;lhfp kykhdJ ntspNawhJ. nrUkYld; tpah;it Vw;gl;L cly; 
Fsph;e;Jf; fhz;g;gLk.;  vl;L ehs; nrd;w gpd;G thjkhdJ fhypy; te;Jr; NrUk;. 
 
Mde;j thjk; (tpiu thjk;) 
tpj;njhUguypy; Njhd;wp tPf;fKq; Fj;Jz;lhFk; 
Rj;jpNa Fly; typj;J RUl;bNkypOj;J thq;Fk; 
njw;wpLkpUghNyhAk; jphpe;jplhirT Fd;Wk; 
kj;jsk; NghNy rj;jk; fjwpLk; ghyd; jhNd.11 
 
tpiuthjnkd;W nrhy;yg;gLk; Mde;j thjk; Foe;ijfspd; tpiu gutpy; 
Njhd;wp tPq;fp Fj;jYz;lhf;Fk;. Fly; nehe;J RUl;b NkNy ,Oj;J itf;Fk;.  
,uz;L fhy;fSk; Xa;;e;J Nghk;. eil jLkhwp elf;f ,ayhJ. mirT FiwAk;.  
Foe;ijapd; FuyhdJ kj;jsk; Nghy; ,Uf;Fk;. 
 
  czf;fy; thjk;  
ciuj;jpLq; ifAq;fhYk; cWg;ngy;yhe; jsh;;e;J;f fhl;b 
epiug;gWq;fOj;J NfhZk; ePh;kyk; nrWj;Jf; nfhs;Sk; 
Jiuj;jpLk; rPjk; Nth;it Jts;Kiy tpUg;gkpy;iy 
fiuj;jpLk; ghitNghNy mlq;fY Kzf;fyhNk.11 
 
czf;fy; thjk; Vw;gl;lhy; if> fhy;> cly; cWg;Gfs; ahTk; jsh;;e;J 
fOj;Jk; NfhZk;. rpWePUk; kyKk; ntspNawhJ. rPjk; tpah;it Njhd;Wk; jha; 
ghy; cz;zkhl;lhJ.  ghit Nghd;W cly; nkypTWk;. 
 
nghUj;J thj Fzk;  
 
mtatk; nghUj;J NjhWk; mjdpy; ePh; fl;Lz;lhFk; 
ftatk; NghNy epd;W fha;rYkjpg Kz;lhk; 
,tarkpFjpahfk; ,rnty;yhkpsfp epw;Fk; 
ctatk; ifAq;fhYk; cWg;ngy;yhk; jsh;;e;J NghNk.11 
 
nghUj;J thjj;jpd; epkpj;jkhf cly; nghUj;Jfspy; ePh;fl;L cz;lhfp 
tPq;fp>NtjidAk>; RuKk; Njhd;Wk;. nghUj;Jfs; ,sfp epw;f;Fk;. if> fhy; 
kw;WKs;s cly; cWg;Gfs; jsh;e;J Njhd;Wk;. 
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Nky; %r;R thjk; 
tUe;jpNa ghyw;nka;apy; tirnfLq;ifAq; fhYk; 
jpUk;gpa mrtwhJ NjfKq; Fsph;;wir ahFk; 
tpUk;gpa tpirjsUk;  tpisj;jpLq; fOj;J NfhZk; 
epuk;gpa rf;jpFd;Wk; epye;jse;JhzplhNj.11 
 
Foe;ijf;F Nky; %r;r thjk; Vw;gl;lhy; if fhy; mirf;f KbahJ.  
cly; Fsph;e;J fhzg;gLk;. cly; jsh;e;J fOj;Jk; NfhZk;. Foe;ijapd; rf;jp 
Fiwe;J epyj;jpy; fhiy Cd;whJ. 
 
mjprhu thj Fzk;  
trq;nfl;Lq; ifAq;fhYk; tise;JNk Fisle;J NghFk; 
frq;fpNa tanwhpe;J fopr;rYk; nghUkyhfp 
tprk;ngw Fsph;r;irAzlhk; tpf;fYk; gdpAk; fhl;Lk; 
krq;fpa Nghjf; Nflhk; mjprhuthj nkd;Nd.11 
-ghythj epjhdk; 
 
mjprhu thjk; Vw;gl;lhy; ifAk; fhYk; tise;J Fioe;J tpLk;.  
tapw;wpy; vhpT cz;lhfp fopr;rYk; nghUkYk; Vw;gLk; cly; Fsph;e;J 
fhzg;gLk;. NkYk; tpf;fYk;> RuKk; Njhd;Wk;. kaf;fKk; Njhd;Wk;. 
 
,j;jifa FwpFzq;fis nfhz;l ghy thjk; vd;Dk; Neha;f;F 
cs;kUe;jhf rpw;whKl;b FbePh; kw;Wk; ntsp kUe;jhf njhf;fzKiwapy;  
ghythj ijyk; cgNahfg;gLj;jg; gLfpwJ. 
 
rpw;whKl;b FbePh; ( thjj;Jf;F f\hak;)  
 
NghjntOthjkJ jPunthUFbePU GfYtJ NfSkpdpjha; 
 Gj;jpnahL nra;jpby; rpj;jpAWNkaJ ghq;fpNdhL Jhq;fhkNy 
NfjkWNth;f; nfhk;guj;ij nts;Ss;spAk; Kl;bNtNuhLSe;J 
 NfSkpdpuz;liufoQ;rtifahnaL xd;whfNt rijj;J 
ePjKWapU gba;gGjdpNyapL mdypl;lijf; FWf;fp 
 epiwa vl;bnyhd;wjha; rPdp Nkypl;lij ,dp FbAkij ae;jp re;jp 
thjNkhL NjfKistj;jp typahdJk; iffhY tpiwaYlNd12 
tskha; jhpg;Gfs; jiy Nehtidj;JNk khWkwp njspthfNt. 
jus kzp gythflk; 
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ghy thjj; ijyk; 
 
jhndd;w ep;d;ngz;nza; chpjhd; gpd;Dk; 
 rhw;WfpNwd; Gs;spgl;l ntw;wpiy rhW chpjhd; 
thndd;w tid tPjk; rkdjhf 
thq;fpNa fufkjp yse;J tpl;L 
Nfhndd;w gOf;fha; ghf;F xUgye;jhd; 
 Fkw miuj;Nj fiuj;J tbj;J nfhz;L 
G+ntd;w fhnril Gfl;L Nknyq;Fk; 
 G+rp tpL ghythjk; NghJk; ghNu.13 
kjiyNeha; njhFjp- 3  
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njhf;fzk;  
njhf;fzk; vd;gJ kh;j;jdk; vdg;gLk;. tspahy; cz;lhf;f $ba 
Neha;fs; vy;yhtw;iwAk; ePf;Ftjw;f;F ,JNt gad;gLk;. ,jd; nra;Kiw xd;gJ 
tifg;gLk;. mit: 
1. jl;ly; 
2. ,Wf;fy; 
3. gpbj;jy; 
4. KWf;fy;; 
5. iffl;ly; 
6. ,Oj;jy; 
7. mOj;jy; 
8. ky;yhh;jy; 
9. mirj;jy; vd;gdthFk; 
,t;Tlypy; cs;s ehbfs; %tif. mit thjk;> gpj;jk;> fgk;. 
njhf;fzj;jpd; gz;G: 
njhf;fzj;jp dhypuj;je; Njhy;C zpitfl;F 
kpf;F rTf;fpaQ;r kPuDk;Ngh - nka;f;fjpf 
Gl;bAwf;fk; Gzh;r;rp apitfjpf;Fk; 
gl;l miyr;ryWk; ghh;. 
nghUl; gz;G Ehy; (rkPuk; - thA) 
 
kh;j;jdk; - jU+ 
 
 kh;j;jd khfpa njhf;fzj; jpd;nray; tFg;NgNd - rjh 
epe;jKk; thjk; gpzpj;j gpzpg;igr; nrfFg;NgNd 
ky;yfuhd gplfh;if------------------ 
   -------- tpdTjp ePKiw ed;whf.14 
       Njud; jU. 
njhf;fzk; clypy; nray;gLk; Kiw:  
fiznaYk;G> KJnfYk;G> gOtpd; tpyhntYk;G> fq;fhs vYk;G Mfpa 
NjhNyhL mize;j vYk;Gfs; Ie;J tifg;gLk;. ,itfs; mike;j clypy; 
thjk; kpQ;Rk;. Mjdhy; mdyhfpa gpj;jk; kpFk;. mjdhy; IaKk; cz;lhFk;. 
Mjyhy; gj;J tifahd thAf;fSk;> ehb gj;Jk; miktdthk;.   
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,tw;iw xOq;FgLj;jpf; nhfs;gth; gjpdhW taJila Fkuidg; Nghy; 
fhzg;gLth;.15 
njhf;fzk; nra;Kiw: 
 clk;gpy; ghprpj;J tUk; fhw;wpdhy; cz;lhfpd;w Neha;f;Fg; 
gpbj;jw;nwhopYk; kUe;J Nghy; nray;gLk;.  vdNt njhf;fzj;jpid twpNj 
gpbj;jyd;wpj; ijyj;ijf; nfhz;Lk; Nkw;nrhd;d 9 Kiwfspy; nra;tJz;L.  
,q;fdk; nra;jpby; clYWg;Gfs; KWf;Nfwp cuk; ngUk;. 
 ,g;ghpfhuk; thjg; gpzpfisnay;yhq; nfLj;J thjg; gpzpapdhy; 
vOe;jpUf;fkhl;lhj nehz;bNghy;thidAk; vOe;J elf;fr; nra;Ak;.  
njhf;fzj;ijr; rhptu nra;tjhy; thj Neha;fisNa ad;wp gpj;j> 
IaNeha;fisAk; mfw;wyhk;.15 
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MODERN ASPECT 
ANATOMICAL LOCALIZATION OF NEUROLOGICAL 
PROBLEMS 
 A clear, precise and accurate history of the entire course of the illness is 
imperative in neurological disorders.  It often leads to a provisional diagnosis and also 
helps to guide the physician towards a more pointed and detailed neurological 
examination.  
 It helps to determine the aetiology, etio pathogenesis, course of events and 
possible sites of lesions.  The onset of disease whether it is acute, sub acute, chronic or 
acute exacerbation of a chronic illness is important in clinical neurology.  Similarly, the 
course of the illness, whether progressive, static, regressive or showing improvement 
from the time of insult are important clues in distinguishing a degenerative brain disorder 
from acute acquired insults.   
Common symptom groups include delayed neurodevelopment, regression of 
neuro development, symptoms such as fits, motor weakness, gait and tone abnormalities, 
altered sensorial states, features of raised intracranial pressure, and sensory symptoms.  
History should evaluate the details of each of the above symptoms and also presence or 
absence of other symptoms’ groups.  A holistic approach is required to assess the overall 
status. 
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CEREBRAL LESIONS: 
 The cerebral cortex functions is an integrated manner, yet certain functions are 
more specifically controlled from various specific sites.  In cerebral cortical insults, the 
localization or preferential involvement of various lobes of the cortex can be obtained by 
history of symptoms related to higher functions and specific signs are; 
S. 
No 
Lobe  in cerebrum The effects of the lesions 
1. 
 
 
 
Frontal lobe 
Disinhibition 
Lack of initiative 
Antisocial behaviour 
Impaired memory 
Incontinence 
Grasp reflexes  
Anosmia 
Seizure disorder 
Plantars extensor 
DTR exaggerated 
2.. 
 
 
 
Temporal lobe 
Dysphasia 
Dyslexia 
Poor memory 
Complex hallucinations (smell, sound, vision) 
Homonymous hemianopia 
Psychomotor seizures 
3. 
 
 
 
Parietal lobe 
Dyscalculia 
Dysphasia 
Dyslexia 
Apraxia 
Agnosia 
Homonymous hemianopia  
Exaggerated deep tendon reflexes 
4. 
 
 
Occipital lobe 
Homonymous hemianopia 
Hemianopic scotomas 
Visual agnosia 
Impaired face recognition 
Visual hallucination followed by convulsion (lights, zig-
zag’s lines) 
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SPINAL CORD: 
 Lesions of the spinal cord often lead to paraplegia or quadriplegia. The onset of 
weakness, pattern of progression, time taken for evolution of the full profile should be 
enquired into.  The associated symptoms which need to be interrogated include history of 
pain, girdle sensation, radicular pain, sensory loss including touch, pain, temperature, 
pressure and posterior column abnormalities are often difficult to elicit in children. A 
definite sensory loss level is hard to define and thus a useful parameter for identification 
of site of spinal cord lesion is not available in childhood.  Involvement of bladder and 
bowel control, peri anal sensations and sphincter tone are important. Presence of 
cutaneous dimple, lipoma, tuft of hair, spinal tenderness, per spinal swelling  should be 
differentiated into compressive or non compressive myelopathies, and extramedullary or 
intramedullary lesions. The clinical feature that help in this regard are listed below. 
 
LESION INVOLVING THE SPINAL CORD AND ITS LOCALIZATION: 
Paraplegia:  It is a symmetric paralysis of both lower extremities. 
Quadriplegia:  It is paralysis of all four extremities.  It is also called as tetraplegia. 
Monoplegia:  it is paralysis of one extremity only. 
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CAUSES OF PARAPLEGIA: 
Cortical causes – Cortical venous thrombosis, cerebral palsy, spino cerebellar hereditary 
spastic paraplegia. 
Spinal causes – Transverse myelitis, epidural abcess, herpes zoster myelitis, GB 
syndrome, poliomyelitis, trauma, and tubercuous osteomyelitis of vertebra. 
Paraplegia in flexion – the pyramidal tracts are severely affected, and there is a lesion of 
descending spinal pathways.  The legs become progressively more flexed at knee and 
hip, and stimulation provokes painful flexor spasm. 
Paraplegia in extension – when spinal lesion is incomplete and affectes principally the 
pyramidal tracts the tone in lower limbs is increased in extensor muscles.      
 
 
FEATURES OF LOCALIZATION IN SPINAL CORD: 
Cord segment Clinical features Muscle paralysed  Reflexes 
C3-C4  
 
 
 
 
 
 
 
 
Pain in neck and 
occipital pain 
paresthesia and 
weakness in upper 
limb early relative 
anesthesia of face 
paralysis of 6
th
, 10
th
 
and 11
th
 cranial 
nerve. 
Lower parts of 
trapezius, supra 
spinatus and infra 
spinatus 
 
Muscle of upper 
limb, Diaphragm 
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C7 
Quadrplegia 
Paraplegia 
 
 
Triceps and 
extensors of wrist 
and fingers 
 
Triceps (C6-7) lost 
C8, T1 
 
 
 
 
 
T6 
Spastic paralysis of 
trunk and lower 
limbs 
Paralysis of ocular 
sympathatheic –  
some times 
Spastic paralysis of 
muscles of 
abodomen and 
lower limbs 
Triceps and 
extensors 
of wrist and fingers 
 
Flexors of wrist and 
fingers and muscles 
of hand. 
Intercostals, upper 
and lower rectus 
abnominis, oblique 
abdominis 
Triceps (C6- 7) lost 
 
 
In upper limb – 
normal, 
exaggeration in 
lower limb 
Upper abnorminals 
and lower 
abdominals lost 
T9- 10 Spastic paraplegia Lower half of rectus 
abdominis 
Upper abdominals 
normal lower 
abdominals lost 
T12L1 Spastic paraplegia Lower fibers of 
obliue abdominis 
and transverslis 
lliopsoas 
 
L3-4 Spastic paraplegia Quadriceps, 
abductors of hip 
Knee jerk (l2-4) lost. 
Ankle jerk + (S1-2). 
S1-2 Flexion of hip, 
adduction of thigh, 
extension of knee 
and dorsiflexion of 
foot possible. 
All other 
movements in lower 
extremities weak 
 
Glutei, calf muscles 
anterior tibial and 
peroneal, small 
muscles of foot 
Knee jerk and Ankle 
jerk lost, plantar 
reflexes lost 
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S3-4 No paraplegia.  
Retention ofurine 
and feces 
Paralysis of external 
sphincter 
Anal and 
bulbocavernous 
reflexes lost.  DTR 
normal  
Cauda Equina 1.Whole cauda – 
aesthesia below 
folds of groin, 
including genitals, 
loss of control of 
bladder and rectum 
2.Upper Sacral and 
L3- sensory loss 
over front and 
posterior and outer 
aspect of thigh 
3.Below S2 – Saddle 
– shaped area of 
anaesthesia, 
incontinence of 
urine and feces 
4. S4-5 and coccygeal 
roots – anesthesia of 
anus and rectum 
Paralysis of lower 
limb 
 
 
 
 
 
 
Paralysis of gluteal. 
Hamstring and all 
muscles below knee 
 
 
 
 
 
No paralysis of 
lower limb 
 
 
 
 
 
 
Paralysis of levator 
ani 
Absent deep reflexes 
 
 
 
 
 
 
 
 
Knee jerk and ankle 
jerk lost 
 
 
 
 
 
 
All reflexes in lower 
limb normal 
16 
TR--- Deep Tendon Reflex 
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PARESIS 
DEFINITION: 
Paresis the term describe weakness.  The term paresis comes from the Ancient 
Greek ―letting go‖ from ―to let go, to let fall‖. 
Paresis is defined as a condition of muscular weakness caused by nerve damage 
or diseases.  It is the medical term for partial paralysis, impaired movement or partial 
loss of movement.  
 It usually refers to the limbs, but it can also be used to describe the muscles of 
the eye Iopthalmoparesis, the stomach (Gastroparesis), and also the Vocal cord (Vocal 
cord oaresis). Neurologists use the term paresis to describe weakness, and plegia to 
describe paralysis in which all voluntary movement is lost. 
17 
DEFERENCE BETWEEN PARESIS AND PARALYSIS: 
 Paresis    - weakness of voluntary movements 
 Paralysis -  in which all voluntary movement is lost 
 
AETIOLOGY : 
This ailment is congenital or acquired in nature. In frequent cases, children are 
found with paralysis of one upper extremity, which appear as a result of injury to the 
brachial plexus during childbirth. Motor activity of hands of the child is limited or 
absent. It is parallel to the body, it has a flattened appearance in the joints. 
It happens that paresis is noted on the hand and foot with the same side or 
exclusively on the feet. This problem is possible, when developing an innate threshold of 
the spinal cord. Paralysis can occur in the child with age, if he at the time of birth has 
diseased brain. Typically, this situation occurs when the child reaches 2 years of age. 
Only an experienced neurologist, highly qualified and can properly diagnose and 
prescribe appropriate therapy. 
Normal muscle function requires communication all along the motor pathway, 
a chain of nerve cells that runs from your brain through the spinal cord and out to your 
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muscles. A complete interruption of communication anywhere along the pathway 
prevents muscle movement resulting in paresis or paralysis. 
Paresis is the condition describing an inefficiency that cause muscle weakness.  
Any condition causing paresis may progress from weakness to paralysis.  And  nerve 
regeneration or regrowth can return strength to a paralyzed muscle. 
A paralyzed muscle may be flaccid, flabby and without tone. Or it may be 
spastic, tight and with too much tone. 
SIGNS AND SYMPTOMS: 
The list of signs and symptoms of paresis are 
 Impaired movements 
 Weakness 
 Tingling 
 Myalgia 
 Numbness 
 Balance issues 
 Vision changes 
 Speech difficulties 
 Increased muscle tone 
 Appearance of pathological reflexes 
SITE OF LEISON: 
The distribuition of paresis or paralysis offers important clues for determining the site 
of nerve damage  
 Monoplegia ~ caused by isolated damage to central or peripheral nervous system 
 Hemiplegia ~ almost always caused by brain damage on opposite side 
of paralysis 
 Diplegia ~ brain damage, most often caused by cerebral palsy 
 Quadriplegia ~ shoulders or higher upper spinal cord damage 
 Paraplegia ~ lower spinal cord injury 
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CAUSES : 
 Causes of broader categories of paresis occur in more medical conditions.  They 
are: 
 Neuromuscular conditions 
 Muscle condition 
 Nervous system condition 
 Movement conditions 
PARESIS IS A COMPLICATION OF OTHER CONDITIONS: 
Other conditions that might have paresis as a complication may, potentially, be an 
underlying cause of paresis.  Following as having paresis as a complication of that 
condition: 
 Electrical burns 
 Sickle cell Anemia 
PARESIS AS A SYMPTOM: 
 Conditions listing paresis as a symptom may also be potential underlying causes 
of paresis.   
 Cutaneomeningospinal angiomatosis 
 Henoch – Schonlein purpura 
 Selected Endocephalities 
 Sickle cell Anemia. 
MEDICATIONS OR SUBSTANCES CAUSING PARESIS: 
 The following drugs, medications, substances or toxins are some of the possible 
causes of paresis as a symptom.  This list is incomplete and various other drus or 
substances may causes your symptoms. Always advise any medications or 
treatments you are using, including prescripition, over – the – counter, 
supplements, herbal or alternative treatments. 
 Seromycin pulvules 
 Cycloserine etc.,  
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 As with all medical conditions, there may be causal factors.  Further relevant 
information on cause of paresis may be found 
 Paresis represent partial paralysis.  In other word, it can be characterized as a 
certain impossibility of performance of various actions and movements because 
of serious defeats important central and peripheral nervous systems. 
Experts conditionally divides this disease into two big groups.  
The first – organic when there is opportunity precisely to find out why the 
concrete  nervous impulse not always reaches a muscle.  
The second group – functional which are diagnosed by dangerous injuries of a 
cerebral coretex. 
 The main type of paresis are nerve paresis, paresis of extremities, paresis of a 
throat and distalny paresis.  Dangerous paresis of a nerve is often partial restrictions of 
actions of muscles  of a body of the person which occurs owing to his concrete part when 
muscle cease to carry out habitual human functions.  This serious frustration mainly is 
connected with violations of nervous system.   
 Other type – paresis of extremities is usually provoked by a dangerous cerebral 
haemorrhage. It considered quite widespread disease among the populations of many 
countries. At least some million people strongly suffer from such partial loss of 
important functionality of extremities. This is only one extremity is immobilized, 
diagnose monoparesis, paraparesis is such illness when two hands or both feet are 
affected.  At tetraparesis bothe the lower and tip extremities badly move. 
 Paresis of throat is an incomplete paralysis extensive guttural area.  It is possible 
to divide this view of three small subspecies.  Miopathichesky paresis is provoked by 
various inflammatory process which are possible in muscles, and also various 
pathologies of nerves, usually carry out ways and even the centres of brain activity.  
Rank laryngitis and tuberculosis as them. 
Neuropatichesky paresis arises because of various changes of the central and 
peripheral nervous systems.  Such serious changes in TsNs always happen because of 
listeriya, and in the peripheral – because of the wandering nerve.  These serious 
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pathologies are quite often connected both with injuries and with other inflammations 
cervical or in chest department. 
Distalny paresis of hands does impossible performance of diverse easy 
movements.  It is divided in two sub groups – central and peripheral.  At such type of a 
disease the patient cannot simply squeeze a hand in a first.  Moreover, quite often tighter 
with such elementary compression there is also an extension in a luchezapyastny joint of 
the sick person. 
PARESIS REASONS: 
 The main reasons for distalny paresis it is possible to note a patrimonial trauma in 
important area of a humeral texture.  Haemorrhages, strokes, tumors, long migraines, 
typical multiple sclerosis considerable defeats of hemispheres of the top cervical 
department of a spinal cord and brain, as well as other injuries are other reasons. 
   The reasons of developing of paresis of a throat covered in polietiologichesky 
pathology.  Quite often this type of a disease develops and against other infectious 
disease.  Quite often paresis of a throat can be diagnosed at such inflammatory disease as 
laryngotracheitis, a typhoid, syphilis, botulism and siringomiyeliya. 
The reasons of paresis of a facial nerve consist available such illness as herpes, 
flu, a rubella, adenoviruses, TsMV and chicken pox.  However completely be not proved 
communication of these disease with paresis front nerva a the majority of cases of 
paresis of extremites by the reasons various injuries and accidents can. 
PARESIS SYMPTOMS: 
Progressive increase of tone of muscle can be referred to the main symptoms of 
this disease.  It is also possible to note serious violation of reflexes and a hyper 
reflection.  Thus the clinical picture of typical paresis of a throat is based from various 
violations of a voice, and breast violations.  It is possible to note its main manifestations 
–  decrease in sonority of a voice, loss of a timbre of a voice, the shepotny speech, 
hoarseness, hoarseness and jingle of a voice. In additionally an important symptom in 
fatigue at insignificant voice loadings. 
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At paresis of extremities it is observed not only increase of a tone of muscles, but 
also essentially violation of reflexes, and also the hyper reflection is noted.  At paresis of 
a facial nerve strong morbidity and quite unpleasant feeling is felt. The Assimitrichnost 
or a partial immovability the preson are the main signs of this type of a disease. Thus it is 
difficult simple to patient to smile and he experience economies difficulties at usual 
conversation. 
 At paresis of a throat serious violation of breath as it is difficult for air to come 
to airways of patient are noticeable. In some patients there is a dangerous asphyxia.  
Typical miopathichesky paresis of a throat with dangerous bilateral defeat is shown by 
considerable violations of a phonation at a neyropathichesky paresis of a throat often 
weakness muscles, and also the extending glottis are noted in the beginning, irritability, 
sleep disorders and fatigue are inherent in all type of paresis. 
At diagnosis of paresis participation of such experts as neuropsychiatrists, 
otolaryngologists, neurosurgeons, psychiatrists and pulmonologists usually is required.  
When diagnosing such disease the important role is played by careful collecting the 
anamnesis, and also detection of tendency of each specific patient to typical psychogenic 
reactions.  
 TYPES OF PARESIS 
 Monoparesis – One leg or one arm 
 Paraparesis – Both legs 
 Hemiparesis – One arm and one leg on either side of the body 
 Triparesis - Three limbs. This can either mean both legs and one arm, both arms  
and a leg, or a combination of one arm, one leg, and face 
 Quadri paresis - All four limbs, equally affected 
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Monoparesis         Hemiparesis  Paraparesis  Quadri paresis 
 
 
One leg or    
one arm 
 
 
MONOPLEGIA 
 
Monoplegia is a paralysis of a single limb, usually an arm.  Common symptoms 
associated with monoplegic patients are weakness, numbness, and pain in the affected 
limb. Monoplegia is a type of paralysis that falls under hemiplegia. While hemiplegia is 
paralysis on half of the body, monoplegia is restricted to a single limb or to a specific 
region of the body. Monoplegia of the upper limb is sometimes referred to as brachial 
monoplegia, and that of the lower limb is called crural monoplegia. Monoplegia in the 
lower extremities is not as common of an occurrence in the upper extremities. 
Monoparesis is a similar condition, but less severe because one limb is very weak in this 
case, not paralyzed.  
 
SIGNS AND SYMPTOMS: 
There are a number of symptoms associated with monoplegia.  
 Curling of the hands or stiffness of the feet,  
 Weakness 
 Spasticity 
 Numbness 
 Paralysis 
 Pain in the affected limb 
 Headaches, and shoulder pain  
 Weakness and loss of sensation in the affected extremity, usually an arm 
 
One arm and 
one leg on 
either side of 
the body 
Both legs All four limbs, 
equally affected 
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PARAPLEGIA : 
Paraplegia is an impairment in motor or sensory function of the lower 
extremities. The word comes from  Greek  "half-striking".  It is usually caused by Spinal 
cord injury or a Congenital condition that affects the neural (brain) elements of the spinal 
canal. The area of the spinal canal that is affected in paraplegia is either the thoracic, 
lumbar, or sacral regions.. 
Spastic paraplegia is a form of paraplegia defined by spasticity of the affected 
muscles, rather than flaccid paralysis. 
HEMIPARESIS : 
Hemiparesis, or unilateral paresis,  is weakness of one entire side of the body  
(hemi - means "half").  Hemiplegia is, in its most severe form, complete paralysis of half 
of the body.   Hemiparesis and hemiplegia can be caused by different medical conditions, 
including congenital causes, trauma, tumors, or stroke.
  
 
SIGNS AND SYMPTOMS   
 Loss of balance. 
 Difficulty walking. 
 Impaired ability to grasp objects. 
 Decrease in movement precision. 
 Muscle fatigue. 
 Lack of coordination. 
 
TRIPARESIS: 
Triparesis is a medical condition, similar to triplegia, but the major difference 
between the two is primarily that triplegia is total loss of function in three limbs, and 
triparesis denotes weakening of three limbs. 
Triplegia is a medical condition characterized by the paralysis of three limbs. A 
person with triplegia can be referred to as triplegic. While there is no typical pattern of 
involvement, it is usually associated with paralysis of both legs and one arm — but can 
also involve both arms and one leg.  
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The condition is commonly associated with Cerebral palsy, although conditions 
such as Stroke can also lead to it. Triplegia has also been found to be due to an Increased 
intracranial proessure associated with hydrocephalous resulting from traumatic brain 
injury.  
A similar condition is trtiparesis,  in which the patient suffers from paresis in 
three limbs, meaning that the limbs are very weak, but not completely paralyzed. 
TETRAPARESIS OR QUADRIPARESIS : 
 
Tetraplegia, also known as quadriplegia, is paralysis caused by illness or injury 
that results in the partial or total loss of use of all four limbs and torsol paraplegia  is 
similar but does not affect the arms. The loss is usually sensory and motor, which means 
that both sensation and control are lost. Tetraparesis or quadriparesis, on the other 
hand, means muscle weakness affecting all four limbs. It may be flaccid or spastic. 
 
SIGNS AND SYMPTOMS :  
 Impairment of the limbs 
 Impairment in controlling bowel and bladder 
 Impairment in digestion, breathing and other autonomic functions numbness 
 Reduced sensation or burning neuropathic pain 
 Spasticity 
 
DIAGNOSIS : 
Diagnosis as spastic or peripheral paresis is based on clinical data.  
 X-ray, magnetic resonance and computed tomography. 
 Two-Dimensional echoencephalography used for infants under 1 year. 
 Radiography of the skull, subarachnoid space and  meninges. 
 Radioisotope methods of diagnosis. 
 Ultrasonic dopplersonography. 
The most common methods, diagnosis is devoted to electron diffraction. This 
technique is extremely important, as it helps to distinguish and diagnose flaccid and 
spastic paresis. It reveals specific changes in the anterior horn of the spinal cord lesions 
and neuropathies, absent with UMNS. In addition, electron diffraction causes a reflex 
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reaction of the muscles, which is called the H-reflexes. Under normal condition the 
patient respond only the calf muscles. While in spastic paresis react all paretic muscles. 
TREATMENT OF PARESIS: 
 Usually primary manifestation of paresis is always considered a certain 
discomfort in muscles. In the absence of necessary treatment it is not excluded that such 
serious disease as paresis will develop into full paralysis.  
The main treatment usually consists in initial identification and further 
elimination of the main reason of developing of a disease.  Special courses of massages 
which are urged to help with support of muscles in a tone as from constant partial 
immobilization they can be atrophied are in addition quite often shown.  At treatment of 
different types of paresis will power of each patient and his determination has important 
value.  
 
REHABILITATION 
Rehabilitation is the main treatment of individuals with paresis. In all cases, the 
major aim of rehabilitation is to regain maximum function and quality of life.  Both 
physical and occupational therapy can significantly improve the quality of life. 
 
PHYSICAL THERAPY: 
Physical therapy (PT) can help improve muscle strength & coordination, mobility 
(such as standing and walking), and other physical function using different sensorimotor 
techniques. Physiotheraphy can also help reduce shoulder pain by maintaining shoulder 
range of motion.Supportive devices, such as braces or slings, can be used to help prevent 
or treat shoulder subluxation in the hopes to minimize disability and pain. A treatment 
method that can be implemented with the goal of helping to regain motor function in the 
affected limb is constraint-induced movment therapy.   This consists of constraining the 
unaffected limb, forcing the affected limb to accomplish tasks of daily living. 
 
OCCUPATIONAL THERAPY: 
Occupational therapists may specifically help with paresis with tasks such as 
improving hand function, strengthening hand, shoulder and torso, and participating in 
activities of daily living (ADLs), such as eating and dressing. Therapists may also 
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recommend a hand splint for active use or for stretching at night. OTs educate patients 
and family on compensatory techniques to continue participating in daily living, 
fostering independence for the individual - which may include, environmental 
modification, use of adaptive equipment, sensory integration, etc. 
 
PROGNOSIS: 
Sudden recovery from paresiS is very rare. Many of the individuals will have 
limited recovery, but the majority will improve from intensive, specialised rehabilitation. 
It is vital to integrate the affected child into society and encourage them in their daily 
living activities. With time, some individuals may make remarkable progress.  
 
PREVENTION OF PARESIS: 
The main prevention of paresis is rationing of loading after restoration of 
functions of muscles.  Also it is recommended to avoid over cooling.  At paresis of throat 
is necessary to exclude long stay in dusty rooms.   
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PROPERTIES OF TRIAL DRUG 
INTERNAL MEDICINE  : CHITRAMUTTI KUDINEER CHOORANAM 
CHUKKU 
NtW ngah;:   
 
mUf;;fd;> mjfk;> Mh;j;ufk;> cgFy;yk;> cyh;e;j> ,Q;rp> fLgj;jpuk;> Rf;F> 
Rz;b> nrhz;b> nrsgd;dk>; nrsth;zk;> etRW> ehfuk;> knes\k>; tpr;t 
Ng\[k>; tpl%ba mkph;jk;> Nth;;fnfhk;G.19 
 
Botanical name :   Zingiber officinale  
 
Family  :   zingiberaceare  
 Useful part  :   Rizome  
Taste    :  Pungent  
Potency   :  Hot  
Division  :   Pungent  
Action         :    Anti ulcer, Antifungal, Anti –oxidant activity, Muscular  
  aches, pains sore throat, cramps, constipation, indigestion,  
            vomiting, hyper tension. 
20
 Effects on Blood clotting,       
   Effects on blood pressure
23
, Laxative 
24
 
 
Phytochemicals  : Cardiac glycoside, Alkaloids, Saponins, Flavanoids,  
  Polyphenools,  Reducing Sugar.
21
 
Gingerol and  
ginerol related compounds - The anti oxidant activity Anti inflammatory 
and   Anti analgesic activity. 
Paradol     Anti oxidant. 
Shogol      Anti oxidant, Anti inflammatory activity. 
Ginger flavanoids    Anti oxidant activity. 
Ginger and its constituents shows                  Antioxidant activity and prevent the damage  
          of  oxidative stress. 
Flavanoids      improve the  cardiac circulation
21
 
Calcium                                                           use as calcium supplement in incidence of  
infants or adults
21 
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Minerals- Calcium, Sodium, Iron, Copper, Zinc, Magnese,      Chromium,   Cadmimum, 
Led Nicle Mercury
21
 
 
Vitamin contents of ginger
 
Thiamin (B1), Riboflavin (B2), Niacin (B3), Panthenic acid (B5), Vitamin B6, 
Vitamin C, Vitamin E
22 
 
nghJ Fzk;: 
thjg; gpzptpz Whjw; nrtptha; 
  typjiy typFiy typapU tpopePh; 
rPjj; njhLthp Ngjpg; gyNuh 
  rpfkyp Kfkf Kfkpb fgkhh; 
rPjr; Ruk;tphp Ngjr; RuNeha; 
njwpgLnkdnkhop Fth;Gtp jdpNy 
<Jf; FjTkp jPJf; Fjth 
njDk;tpjp apiyet RWFz KdNt.19 
(Njiuah; Fzthflk;) 
 
R+iyke;jk; neQ;nrhpg;G NjhlNkg gk;;kio 
%yk; ,iug;gpUky; %f;FePh;-thyfg 
Njhlkjp rhue; njhlh;thj Fd;kePh;j; 
Njhlk;M kk;Nghf;FQ; Rf;F. 
     (mfj;jpah; Fzthflk;) 
 
Medicinal uses: It is used to treat dyspepsia, throat complaint , chronic vatha diseases, 
gastro intestinal and respiratory disease.  
 
ARATHAI 
NtW ngah;  : rpw;wuj;;ij> Nguuj;ij25 
Botanical name :  Alpinia officinarum  
English Name :      Galangal the lesser  
Family  :   zingiberaceare  
 Useful part  :  Rizome  
Taste    :  Pungent  
Potency   : Hot  
Division  :  Pungent  
Action:     Expectorant, Febrifuge, Stomachic. 
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Phytochemicals  :   volatile oil, diaryheptanoid , sterol and flavonoids ,  
Galangoflavonoid 1’S-1’-acetoxychavicol acetate, phenylpropanoids and 
phydroxybenzaldehyde , acetoxycineoles, β-Sitosterol diglucoside (AG-7) and β-sitsteryl 
Arabinoside (AG-8) , The phenylpropanoids glucopyranosides, (glucopyranoside, and 
glucopyranoside 
26 
 
Minerals and Vitamins - Sodium, Iron, Vitamin A, Vitamin C
27 
Ethonobotanic  action:Activity Smoothening the blood flows in our body, As a cure for 
diarrhea
27
.antioxidant, antibacterial, anti-inflammatory, anticancer, antiproliferative, 
inhibition of enzymes, as well as the inhibition of nitric oxide production. 
28.  
Cardio 
protective, hepato protective, Analgesic, Neuro protective
29
, Antihyperlipidemic 
bioactivity
30
, Anti hyperlipidimic 
31 
 
nghJFzk;:  
njhz;ilapw;fl; Lq;fgj;ij;j Jhuj; Juj;jptpLk; 
gz;ilr;rP jj;ijg; gwf;fbf;Fk; - nfz;iltpop 
kpd;Nd! fug;gidNt whf;Fk; grpnfhLf;;Fk; 
nrhd;Ndhk; muj;ijr; Rfk;.25 
(mfj;jpah; Fzthflk;) 
 
khh;ig alh;gpzpR thrfh rk;%yk; 
Nrhigjl;lr; R+h;thj Nrhzpj Neha; - jPgr; 
Ruj;ij aLg;Ghl;gy; JhUWfz; Nehpd; 
muj;ij naLJfs jhk; 
    (Njiuah; Fzthflk;) 
 
muj;ijapd; Fzj;ijf;NfsPh; mf;fuQ; rd;dp Nghf;Fk; 
cuj;njhU ,Uku; khw;Wk; Xq;fpa cjpuk; Nghf;Fk; 
,iuj;jpLq; fhr nkl;L;k; tpQ;rpa \aKe; jPUk; 
Ruj;ijAk; ePf;F nkd;W nrhd;dK Ntj EhNy. 
(VL) 
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rpw;wuj;ijapd; rpwg;G 
thjgpj; jq;fug;ghd; thjQ; rpNuhNuhfQ; 
Nrhh;e;jfg Kj;NjhlQ; rPjnkhL - Neh;e;jRuk; 
kw;wuj;ijf; fhl;b tUkpUk Ye;jPUk; 
rpw;wuj;ij td;kUe;jhy; Njh;. 
(Njiuah; Fzthflk;) 
 
 VELLULI 
 
NtW ngah;  :  ,yRdk;> fhak>; cs;sp> G+z;L> nts;isg;G+z;L>32 
           nts;tq;fhak ; 
Botanical Name :    Alluim sativum   
 English Name  :  Garlic 
 Family   : Amaryllidaceae  
 
 Organoleptic Character  
 Taste      : Pungent 
 Potency  :  Hot  
Division  :  Pungent  
 
nghJFzk;:  
 rd;dpnahL thje; jiyNehT jhs;typ 
kd;dptU ePh;;fNfhit tdprPjk;- md;dNk! 
cs;Ss;sp fz;gha; cis%y NuhfKk; Nghk; 
nts;Ss;sp jd;dhy; ntUz;L.32 
(mfj;jpah; Fzthflk;) 
Actions:   
 Carminative , Tonic , Alterative , Stimulant ,Expectorant , Diuretic , Anthelmintic.  
 
Phytochemicals: Flavanoids, Sulphur containing compounds: Dially sulphate, .
33
 Allicin, Alliin, 
Ajoene, enzymes-allicinase, B vitamins, Minerals, Flavanoids, β- Carotene, Niacin, Riboflavin, 
Thiamin, Protein, Volatile oil, Vitamin A, B1, B2 and C Calcium copper, germanium, iron, 
magnesium,. Manganese, phosphorous, phytoncides, potassium, selenium, unsaturated aldehydes 
Zinc and enzymes.
34
 Carbohydrate
35 
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Activity: 
 
 Cardio protective, Neuro protective, Anti thrombotic, Anti oxidant, Anti hyper 
tensive, Anti hyper lipidimic
36 
, Effect on Protein and Fat profile
37 
 
 CITTRAMUTTI 
 
NtWngau;   :   rpWe;njhl;b> rpWe;njhl;il> rpW FWw;njhl;b> rpw;whKl;b38 
Botanical Name :  Pavonia zeylanica 
English Name :  Yellow sticky Mallon 
Family  : Plumbaginaceae 
Useful Part  : whole plant 
 
Organoleptic Character  
 
 Taste      : Astringent 
 Potency  : Coolant  
Division  :  Sweet 
Action   : Emollient 
 
 
nghJFzk;: 
mj;jp Ruk;Kjy; mde;jRuk; gpj;jKk; Nghk; 
nkj;j tpopf;nfhpsahk; tPWjap-yj;jp;wfhk; 
ew;wh kiuj;jpUT ehL nkopw;wpUNt! 
rpw;whKl; bj;Jiur; nrg;G.38 
(mfj;jpah; Fzthflk;;)  
 
Phyto chemicals: free radical scavenging molecules, such as vitamins, 
terpenoids, phenolic acids, lignins, stilbenes, tannins, flavonoids, quinones, coumarins, 
alkaloids, amines, betalains, and other metabolites, which are rich in antioxidant 
activity.
39 
 
Ethanobotanic Action: 
 
Antioxidant, anti-atherosclerotic, antitumor, cardiovascula
39 
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ULUNTHU 
NtWngah;  :  cSe;J> khlk>; kh\k;40 
Botanical Name :  Vigna mungo  
English Name : Black gram   
Family  :  Fabaceae 
Useful Part  : Seed. 
 
Organoleptic Character  
 Taste      : Sweet 
 Potency  : Coolant  
 Division  :  Sweet 
Action   : Demulcent, Refrigerant, Aphordisiac, Galactagogue,  
    Nervine tonic,  Nutritive. 
Phytochemicals  : Antioxidant, Anti inflammatory, Protective action for   
   Neuro degernative disease.   
 
nghJFzk;:  
 
nra;avSe; jpw;Fr; rpNyj;ktdp yw;gpwf;Fk; 
nta;apgj;jk; Nghke;jk; tPWq;fhz;-nka;ajdpy; 
vd;GUf;fp jPUk; ,Lg;Gf; fLgykhk; 
Kd;G tpUj;jpAz;lha; Kd;.40 
(mfj;jpah; Fzthflk;) 
 
Phytochemicals: Nutritional value – Carbohytrates, Dietary fibers, Fat, Protein, 
Vitamins- Thiamine (B1), Ribo flavin (B2), Niacin (B3), Panothenic acid (B5), Vitamin 
(B6), Folate (B9), choline, Vitamin C,E, K, Amnio acids
41. 
Minerals Calcium, Iron, 
Magnesium, Manganese, Phosphorus, Potassium, Sodium, Zinc, copper, Flavonoids, 
Terpenoids, quinon, sterols, oil and fat
42
.  saponoin, alatonine, tocopherol,tochotrienol,, 
linolenic acids
44 
 
Ethanobotanic Action : Against oxidative stress,, better stress tolerance
42
 The grip 
strength, Locomotion activity and hanging time were also significantly improved
43
 The 
seeds are sweet, laxative, aphrodisiac, tonic, appetizer,  paralysis, rheumatism and 
affections of the nervous syste.
44
   
 44  
VEPPA ENNAI  
 
NtWngah;   :  mhpl;lk>; Jj;ij> epk;gk>; ghhpgj;jpjuk;> gpRke;jk>; thjhhp> 45  
           Ntg;G 
Botanical name : Azadiracta indica  
English name  : Neem oil  
Family  :  Meliaceae.  
 
Organoleptic Character   
Taste    :    Bitter  
Potency   :  Hot   
Division   :  Pungent  
 Used parts   :   Seeds  
 
nghJFzk;: 
thjk;Nghk; gpj;jkpFk; khwhf;fp ue;jpnahL 
NkhJfug; ghd;rpuq;F Kd;dprpTk;-XJlypd; 
ehg;g ZWRuK ehLrd;dp Ae;njhiyAk; 
Ntg;gnea; nad;nwhUf;fhy; tps;S. 
(mfj;jpah; Fzthflk;) 
 
Action   :   Anthelmintic, Stimulant, Antiseptic, Insecticide, Discutient. 
Phytochemicals :   Nimbin, Nimbinin, Nimbidin
47 
Ethanobotanic Action :   Anti inflammatory, Reduce the Muscle pain
46
, protects against free  
    radicles, Balance pita and kapha doshas
47 
 
VETRELAI 
 
NtW ngah;:  ntw;wpiy> jhk;G+yk;> jhk;G+yts;sp> jpiuay;> ehfty;yp> 
nky;ypif> nts;spiy> nky;ylF.48 
 
Botanical name : Piper betle 
English name  : Betal leaf 
Family  : Piperaceae.  
 
Organoleptic Character   
Taste    :    Carminative, Hot 
Potency   :  Hot  
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Division   : Hot 
 Used parts   :   Leaf   
Actions : Stimulant, Carminative, Astringent, Aphrodisiac,  
    Antiseptic,    Febrifuge, Stomachic, Galactagogue,      
  Sialogogue. 
 
Phyto chemicals:  Nutients, Antioxidants, minerals, vitamins phytochemicals, proteins, 
fat fibers, calcium and iron etc.  Flavanoids, Tannis, Saponins, Alkaloids, Terphenoids. 
Neurological disease- chewing betel nut with tobacco was a significant predictor for 
Meige’s Syndrome, a neuro degernative disease.49 
 
Chemical constituents:
 
 Poly Phenolic compounds, alkakids, tannins, arecoline, areaidine, and fibers.  
This is one and  one of 54 Areca species known to contains alkaloids
50 
 
Pharmacological activites:
 
 Blood pressure regulating activity, Hypo glycemic activity, Antidepressant 
activity, Anti convulsant activity, Central nervous system stimulant,
50
 Anti oxidant, 
Anahgesic, Anticholesteroloemic action
54 
 
Nutritional composition: Water, Protein, Fat, Minerals, Fiber, Chlorophyll, 
Carbohydrate, Engergy, Essential oils, Iodine, Iron, Calcium, Potassium, Nicotinic acid, 
Vitamin C, Vitamin A, Thiamine, Riboflavin, Tannin, Nitrogen, Phosphorus
54 
 
nghJFzk;: 
Iak; mWq;fhz; mjd;fhuq; nfhz;lf;fhw; 
Igar; rapj;jpak;Nghk; ige;njhbNa!- nka;apd; 
fbapd; Fzk; Nghfq; fhuntw;wp iyf;Fg; 
gbAKh; Njhlkpijg; ghh;. 
(mfj;jpah; Fzthflk ;) 
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PAAKU 
 
NtW ngah;;  :  ghf;F> fKF>kuk>; Re;jp> milf;fha;.51 
Botanical name :   Areca catechu 
English name  :  Betel – nut - palm 
Family  : Arecaceae.  
 
 
Organoleptic Character   
 
Taste    :    Astringiant 
Potency   :  Hot  
Division   : Carminative 
 Used parts   :   Nut 
Actions  : Stimulant, Astringent, Taenifuge. 
Actions  : Stimulant, Astringent, Taenifuge. 
 
Phytochemicals : Arecaine. arecaine, arecoline, arecaidine, arecolidine, guvacoline, 
guvacine, isoguvacine,tannin,  red fat, resin, kernel,  gallic acid and a gum.
52
  
 
Ethanobotanic Action:  Laxative, antioxidant, antiseptic, 
52
Astringent,  Mild stimulant
53 
 
nghJFzk;: 
fe;jpapd; fha;jpdf; faj;jpid aWj;jpLk;. 
(Njiuah; fhpry;) 
 
PANAI VELAM 
 
NtWngah;  : gid> jhyk>; fUk;Gwk>; Vlfk;> fhkk>; jUtpuhfd>;  
   jhsp 
Botanical name : Borassus flabellifer 
English name  :  Palmyra palm 
Family  : Arecaceae.  
 
Organoleptic Character   
 
Taste    :    Sweet 
Potency   :  coolant 
Division   : Sweet 
 Used parts   :   Juice  
 47  
 
Actions : Demulcent, Diuretics, Atringent, Aphordisiac, Nutient, Refrigerant, Stimulant, 
Antiphlogistic. 
 
nghJFzk;: 
 
------------------------------------------------------------------------- jq;Fgid 
nty;yj;jhy; thjgpj;jk; tPWfgQ; rd;dpNeha; 
ty;yUrp Fd;kkW khy; 
      (mfj;jpah; Fzthflk;) 
 
Phytochemicals: Vital vitamins and minerals, Iron, Phosphorus, Calcium
55 
 
Ethanobotanic actions: Relieve constipation, blood purifier, prevents free radicals, 
increase hemoglobin blood, relief from cramp, maintaining the normal body temperature, 
controls the blood pressure, Relives the aches and pain, strengthen the bone, building the 
muscle
55 
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INTERNAL MEDICINE : CHITRAMUTTI KUDINEER 
                            
         CHUKKA (Zingiber officinale)          ARATHAI (Alpinia officinarum) 
                                                   
          
           
                ULUNTHU (Vigna mungo )    POONDU ( Alluim sativum )  
  
ARATHAI (Pavonia zeylanica ) 
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EXTERNAL MEDICINE:  BAALA VAATHA THYLA 
 
  VETRELAI (Piper betle)     PAAKU ( Areca catechu) 
 
 
        VEPPENNAI (Azadiracta indica ) 
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PREPARED MEDICINE 
CHITRAMUTTI KUDINEER CHOORANAM (INTERNAL) 
 
 
 
 
 
 
 
 
 
 
 
 
BAALVAATHA THAILAM (EXTERNAL) 
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MATERIALS AND METHODS 
STANDARD OPERATIVE PROCEDURE 
SOURCE OF RAW DRUGS: 
 The required raw drugs for preparation of ―CHITRA MUTTI KUDINEER‖ 
(Internal) and ―BAALA VAATHA THYLAM‖ (External) was purchased from a well 
reputed country shop.  That raw drugs were authenticated by the competent Authority of 
Medicinal Botany department. Then the medicines were purified and prepared in 
Gunapadam Laboratory of National Institute of Siddha. After proper purification, the  
prepared medicines was authenticated by the guide and concerned head of the 
department for its completeness. 
INTERNAL MEDICINE: CHITRAMUTTI KUDINEER CHOORANAM 
 
Ingredients: 
Chukku  (Zingiber officinale) Rhizome     - 21/2 Kalanju (12.5g) 
Arathai (Alpinia officinarum) Rhizome            -  21/2 Kalanju (12.5g) 
            Poondu (Allium sativum) Bulb                             -   21/2 Kalanju (12.5g) 
            Chitramutti ver (Pavonia zeylanica) Root            -   21/2 Kalanju (12.5g) 
Ulunthu (Vigna mungo) Seeds                             -   21/2 Kalanju (12.5g) 
            Thaneer                                                               -   2 padi ( 1120ml)  
 
PURIFICATION OF RAW DRUGS : 
 
 
Purification of Chukku: 
 
 The know quantity of chukku is taken then Soaked in lime stone water for a 
period of time and then dried in shade. Then the outer skin is peeled off . 
 
Purification of Arathai: 
The outer skin of arathai is peel off and made in to small pieces and then dried in 
sunlight 
 
 Purification of Poondu: 
The outer skin of poondu is peeled and made in to small pieces         
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Purification of Chitramutti ver: 
The outer covering of chittra multi was peeled out and made into pieces and then 
dried in sunlight. 
 
Purification of Ulunthu: 
  ulunthu was washed in running water and the outer skin was peeled off 
18 
     
Preparation method :
  
 2 kalanju of Purified Chukku (Zingiber officinale), Arathai (Alpinia 
officinarum), Poondu (Allium sativum), Chitramutti ver (Pavonia zeylanica), Ulunthu 
(Vigna mungo) was taken.   They are dried and made into a coarse powder and then 
soaked it in vessel containing water of 2 padi and heated till it comes to 1/8 th of its 
volume. 
12 
 
Drug Storage: 
The kudineer chooranam was stored in air tight container 
 
Dose: Dosage was advised as  5-15 ml twice  a day, according to the age of the children.  
Adjuvent  :   Canesuga(medicine was advised to take along with palm jaggery)  
Duration :  1Mandalam (45Days) (kudineer for the treatment of baalavaatham was 
advised to take for  1Mandalam (45Days)) 
Dispensing :    
          The kudineer chooranam was made in to decoration and provided to IP patients 
and for OP patient Chooram was packed and dispensed in clean packets. 
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EXTERNAL MEDICINES: BAALA VAATHA THYLAM 
 
Ingredients: 
    Paaku (Areca catechu)                    -  1palam (35g) 
                            Vetrelai (Piper betttle) juice           -  672 ml 
                            Neem oil (Azhadiracta indica)       -  672 ml 
 
Method of preparation: 
The areca catechu was cleaned and made into paste form by adding water and 
then the filtered piper bettle  juice and Neem oil was added  with the paste and allowed it 
to boil till it attained the suitable consistency and, finally filtered  and stored in clean 
container.
13 
 
Drug storage: 
The prepared medicated oil is stored in a clean and dry air tight container. 
 
Method of Application:  
Advised to apply the medicated oil over the affected area and then massage 
gently  once in a day 
 
Duration :  The medicine was advices to use for 45 days 
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PRE CLINICAL STUDY 
PHYSICO CHEMICAL ANALYSIS OF CHITRA MUTTIE 
KUDINEER CHOORANAM 
 
1. Loss On Drying: 
 An accurately weighed 2g of Chitramutti kudineer chooranam formulation 
was taken  in a tarred glass bottle.  The curde drug was heated at 105
0
c for 6 hours in an 
oven till a constant weight. The percentage moisture content of the sample was 
calculated with reference to the shade dried material. 
 
2. Determination of total ash: 
 Weighed accurately 2g of Chitramutti Kudineer Chooranam formulation was 
added in crucible at a temperature 600
0
c in a muffle furnace till carbon free ash wash 
obtained.  It was calculated with reference to the air dried drug. 
 
3. Determination of acid insoluble ash: 
 Ash above obtained, was boiled for 5min with 25ml of IM Hydrochloric acid and 
filtered using an ash less filter paper. Insoluble matter retained on filter paper was 
washed with hot water and filter paper burnt to constant weight in a muffle furnace.  The 
percentage of acid insoluble as was calculated with reference to the air dried drug. 
 
4.Determination of water soluble ash: 
 Total ash 1g was boiled for 5min with 25ml water and insoluble matter collected 
on an ash less filter paper was washed with hot water and ignited for 15min at a 
temperature not exceeding 45
0
c in a muffle furnance. The amount of soluble ash is 
determined by drying the filtrate. 
 
5. determination of water soluble Extracive: 
 5gm of air dried drug, coarsely powered Chitramutti Kudineer Chooranam 
was macerated with 100ml of distilled water in a closed flask for twenty- four hours, 
shaking frequently.  The solution was filtered and 25ml of filtrated was evaporated in a 
tarred flat bottom shallow dish, further dried at 100
0
c and weighted.  The percentage of 
water soluble extractive was calculated with reference to the air dried drugs. 
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6. determination of alcohol soluble extractive: 
 2.5gm of air dried drugs, coarsely powdered Chitramutti Kudineer Chooranam 
was macerated with 50ml. Alcohol in closed flask for 24 hrs.  With frequent shaking, it 
was filtered rapidly taking precaution against loss of alcohol.  10ml of filtrate was then 
evaporated in a tarred flat bottom shallow dish, dried at 100
0
c and weighted.  The 
percentage of alcohol soluble extractive was calculated with reference to air dried drug. 
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PRELIMINARY PHYTOCHIAL CREENING CHIRUTTI KUINEER 
CHOORANAM 
 
The preliminary phytochemical screening test w carried out for each extracts of 
Chitramutti Kudineer Chooranam as per the standard procedure. 
 
1.Detection of alkaloids:  
Extracts were dissolved individually in dilute Hydrochloric acid and filtered. 
a) Mayer’s Test:  Filtrates were treated with Mayer’s reagent (Potassium Mercuric 
Iodide).  Formation of yellow coloured precipitate indicates the presence of alkaloids. 
 b) Wager’s Test:  Filtrates were treated with Wagner’s reagent (Iodine in Potassium 
Iodide).  Formation of  brow/reddish precipitation indicates the presence of alkaloids. 
c) Dargendroff’s Test:  Filtrates were treated with Dargendroff’s reagent (solution of 
Potassicum Bismuth Iodide).  Formation of red precipitation indicates the presence of 
alkaloids. 
d) Hager’s Test:  Filtrates were treated with Hager’s reagent (saturated picric acid 
solution).  Presence of alkaloids confirmed by the formation f yellow colored 
precipitation. 
 
2. Detection of carbohydrates: 
Extracts were individually in 5ml distilled water and filtered.  The filtrates were 
used to test for the presence of carbohydrates. 
a) Molisch’s test: 
To 2ml of plant sample extract, two drops of alcoholic solution of α- naphthol are 
added.  The mixture is shaken well and few drops of concentrated sulphuric acid is added 
slowly along the side of test tube.  A violet ring indicates the presence of carbohydrates. 
 
b) Benedict’s Test: 
Filtrates were treated with Benedict’s reagent and heated gently.  Orange red 
precipitation indicates the presence of reducing sugars. 
 
3. Detection of glycosides: 
Extracts were hydrolyzed with diluted HCL, and then subjected to test for 
glycosides. 
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a) Modified Borntrager’s Test:  Extracts were treated with Ferric Chloride solution and 
immersed in boiling water for about 5 minutes.  The mixture was cooled and extracted 
with equal volumes of benzene.  The benzene layer was separated and treated with 
ammonia solution.  Formation of rose-pink colour in the ammonical layer indicates the 
presence of anthranol glycoside. 
b) Cardiac glycoside (Keller- Killiani test):  Extract was shaken with distilled water 
(5ml).  To this, glacial acetic acid (2ml) containing a few drops of ferric chloride was 
added, followed by H2SO4 (1ml) along the side of the test tube.  The formation of brown 
ring at the interface gives positive indication for cardiac glycoside and violet ring may be 
appear below the brown ring. 
 
4. Detection of saponins: 
a) Froth Test:  Extracts were diluted with distilled water to 20ml and this was shaken in 
a graduated cylinder for 15minutes.  Formation of 1cm layer of foam indicates the 
presence of saponins. 
b) Foam Test:  0.5gm of extracts was shaken with 2ml of water.  If foam produced 
persists for ten minutes it indicates the presence of saponins. 
 
5. Detection of phytosterols: 
a) Salkowski’s Test:  Extracts were treated with chloroform and filtered.  The filtrates 
were treated with few drops of conc. Sulphuric acid, shaken and allowed to stand.  
Appearance of golden yellow colour indicates the presence of triterpenes. 
6. Detection of phenols Ferric Chloride Test:   
Extracts were treated with 3- 4 drops of ferric chloride solution.  Formation of 
bluish black colour indicates the presence of phenols. 
7. Detection of tannins Gelatin Test:  
The extract is dissolved in 5ml of disilled water and 2ml of 1% solution of 
Gelatin containing 10% NaCl is added to it.  White precipitates the presence of phenolic 
compounds. 
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8. Detection of Flavanoids: 
a) Alkaline Reagent Test:  Extracts were treated with few drops of sodium hydroxide 
solution.  Formation of intense yellow colour, which becomes colourless on additional of 
dilute acid, indicates the presence of flavonoids. 
b) Lead Acetate Test:  Extracts were treated with few drops of lead acetate solution.  
Formation of yellow colour precipitation indicates the presence of flavonoids. 
9. Detection of proteins and aminoacids: 
a) Xanthoproteic Test:  The extracts were treated with few drops of conc. Nitric acid.  
Formation of yellow colour indicates the presence of proteins. 
b) Ninhydrin Test:  To the extract, 0.25% w/v ninhydrin reagent was added and boiled 
for few minute.  Formation of blue colour indicates the presence of amino acid. 
10. Detection of diterpenes copper Acetate Test: 
Extracts were dissolved in water and treated with 3-4 drops of copper acetate 
solution.  Formation of emerald green colour indicates the presence of diterpenes. 
11. Gum and Mucilages: 
To 1ml of extract add 2.5ml of absolute alcohol and stirring constantly.  Then the 
precipitate was dried in air and examine for its swelling properties.  Swelling was 
observed that will indicate presence of gum and mucilage. 
12. Test for Fixed oils and Fats: 
a. Spot test:  A small quantity of extract is pressed between two filter papers.  Oil stain 
on the paper indicates the presence of fixed oils. 
13. Test for Quionones: 
Extract was treated with sodium hydroxide blue or red precipitate indicates the 
presence of Quiones. 
The premilinary phytochemical studies of acqueous extract of  Chitramutti 
Kudineer Chooranam were done using standard procedures.  The present study reveals 
that the bioactive compounds were present in all the extracts of Chitramutti Kudineer 
Chooranam. 
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BIOCHEMICAL EVALUATION 
  Experimental procedure:   
5 g of Chittra Mutti Kudineer Chooranam was taken in a 250 ml of clean beaker 
and 50ml of distilled water was added to it. Then it was boiled well for about 10 min. 
Then it is allowed to cool and filtered in a 100 ml volumetric flask and made up to 100 
ml with distilled water. This preparation is used for the qualitative analysis of acidic/ 
basic radicals and biochemical constituents in it.  
Preparation of extract:   
5gm of Chittra Mutti Kudineer Chooranam is weighed accurately and placed in a 
250ml clean beaker and 50ml of distilled water was added with it. Then it was boiled 
well for about 10 minutes. Then it was allowed to cool and filtered in a 100ml volumetric 
flask and made up to 100ml with distilled water. The bio-chemical analysis of Chittra 
Mutti Kudineer Chooranam was done at Biochemistry lab, National Institute of siddha, 
Chennai-47.  
Preliminary test for Copper, Sodium, Silicate and Carbonate:  
 Test for Silicate: 
A little (500mg) of the sample is shaken well with distilled water.  
A little (500mg) of the sample is shaken well with con. HCl/Con. H2So4.  
 Action of Heat:  
A small amount (500mg) of the sample is taken in a dry test tube and 
heated gently at first and then strong.  
 Flame Test:  
A small amount (500mg) of the sample is made into a paste with con. HCl 
in a watch glass and introduced into non-luminous part of the Bunsen flame.  
 Ash Test:  
A filter paper is soaked into a mixture of sample and dil. cobalt nitrate 
solution and introduced into the Bunsen flame and ignited.  
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Test For Acid Radicals  
 Test For Sulphate: 2ml of the above prepared extract was taken in a test tube 
and 2ml of 4% dil. ammonium oxalate solution was added.  
 Test For Chloride: 2ml of the above prepared extracts was added with 2ml of 
dil-HNO3 until the effervescence ceases off. Then 2 ml of silver nitrate solution 
was added.  
 Test For Phosphate: 2ml of the extract was treated with 2ml of con.HNo3 and 
2ml of dil. ammonium molybdate solution.    
 Test For Carbonate: 2ml of the extract was treated with 2ml dil. magnesium 
sulphate solution  
 Test For Nitrate:1gm of the substance was heated with copper turning and 
concentrated H2SO4 and viewed the test tube vertically down.  
 Test For Sulphide: 1gm of the substance was treated with 2ml of con. HCL  
 Test For Fluoride & Oxalate: 2ml of extract was added with 2ml of dil. Acetic 
acid and 2ml dil. calcium chloride solution and heated.  
 Test For Nitrite: 3drops of the extract was placed on a filter paper, on that-2 
drops of dil. acetic acid and 2 drops of dil. Benzidine solution were placed.  
Test For Basic Radicals  
 Test For Lead: 2ml of the extract was added with 2ml of dil. potassium iodine 
solution.  
 Test For Copper: One pinch (50mg) of substance was made into paste with con. 
HCl in a watch glass and introduced into the non-luminous part of the flame.  
 Test For Aluminium: In the 2ml of extract dil. sodium hydroxide was added in 5 
drops to excess.  
 Test For Iron: a.To the 2ml of extract add 2ml of dil. ammonium solution b. To 
the 2ml of extract 2ml  thiocyanate solution and 2ml  of con HNo3 is added  
 Test For Zinc: In 2ml of the extract dil.sodium hydroxide solution was added in 
5 drops to excess and dil.ammonium chloride was added 
 Test For Calcium: 2ml of the extract was added with 2ml of 4% dil.ammonium 
oxalate solution   
 Test For Magnesium: In 2ml of extract dil.sodium hydroxide solution was 
added in drops toexcess.  
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 Test For Ammonium: In 2ml of extract 1 ml of Nessler's reagent and excess of 
dil. sodium hydroxide solution were added.  
 Test For Potassium: A pinch (25mg) of substance was treated  with 2ml of dil. 
sodium nitrite solution and then treated with 2ml of dil. cobalt nitrate in 30% dil. 
glacial acetic acid.  
 Test For Sodium: 2 pinches (50mg) of the substance was made into paste by 
using HCl and introduced into the blue flame of Bunsen burner.  
 Test For Mercury: 2ml of the extract was treated with 2ml of dil. sodium 
hydroxide solution.    
 Test For Arsenic: 2ml of the extract was treated with 2ml of dil. sodium 
hydroxide solution.  
Other constituents  
 Test For Starch : 2ml of extract was treated with weak dil. iodine solution   
 Test For Reducing Sugar: 5ml of Benedict's qualitative solution was taken in a 
test tube and allowed to boil for 2 minutes and added 8 to 10 drops of the extract 
and again boil it for 2 minutes.   
 Test For The Alkaloids: a) 2ml  of the extract is treated with 2ml of dil. 
potassium iodide solution.    b) 2ml of the extract is treated with 2ml of dil.picric 
acid.  
 Test For Tannic Acid: 2ml of extract was treated with 2ml of dil. ferric chloride 
solution  
 Test For Unsaturated Compound: In the 2ml of extract 2ml of dil. Potassium 
permanganate solution was added.   
 Test For Amino Acid: 2 drops of the extract was placed on a filter paper and 
dried well, and then 20ml of Burette reagent was added in it.  
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TOXICITY STUDIES OF CHITTRA MUTTI KUDINEER 
To evaluate the safety profile of Chittra mutti kudineer  short term toxicity study 
carried out as followed. The principles of laboratory animal care were followed and the 
Institutional Animal Ethical Committee approved the use of animals and the study 
design. IAEC registered and approval number: (IAEC). (NIS/IAEC/-IV/06/05012017 
dated 05.01.2017) for Acute toxicity study. 
 Experimental Animals:  
Species                  :  Wistar albino Rats  
Sex         :  Male and Female  
            Age/weight  at start of test   :  6 weeks/140-160g b.wt  
Acclimatization Period          :  7 days prior to dosing  
Housing                 :  Individually in polypropylene cages and  
                                     bedding with      Husk  
Husbandry      :  12-h light/12-h dark artificial        
                         photoperiod/Room temperature  22°C±3°C   
                         and relative  Humidity30–70% 
Feed and Water     :   Rodent pelleted feed RO purified water   Ad 
libitum   Identification     :  Animals were kept in polypropylene Cages and  
                                                            numbered 
 
 Experimentation Details of  Acute Toxicity Study:  
Groups/Treatment regimen   :  Grouped by randomisation 
 Test Guideline       :  WHO guideline 
 Length of exposure to test substance :  Single dose (1Day) 
 No of Animals       :  5 Female+ 5 Male / group 
 Control group       :  Vehicle (palm sugar) 
 Test groups        :  Chitra mutti kudineer 2 ml/kg.b.wt  
  
The wistar albino rats of both sex weighing 150-200g was obtained from 
authorized animal breeders of animal laboratory in TANUVAS, Madavaram, Chennai 
and stocked in animal house at National Institute of Siddha, Chennai. Animals were 
housed in cages at 22°C±3°C and relative humidity 30–70% and have free access to 
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standard rat pellet diet (Sai Meera Foods Pvt. Ltd., Bangalore). The animals are dosed 
with Chittra Mutti Kudineer by oral for one day and monitored for behavioural 
parameters for the first 4 hours after drug administration. Body weight of the animal was 
monitored every week  and recorded .  Animals were weighed and sacrificed under  the 
injection of Pentothal Sodium on the 15
th
day of the Study period.  The toxicological 
effect was assessed on the basis of mortality.  
 Preparation of Test Drug Doses: 
Groups Number of rats 
Group I:   palm sugar 10 (5M+5F) 
GroupII:   Chittramutti 
Kudineer(2ml(10X)*/kgb.wt) 
10 (5M+5F) 
 
          *(1x=2.7ml)      Total 20(10M+10F) 
Route of administration  
Oral route were selected because it is the normal route of clinical administration.  
 
Administration of Dose  
The animals were kept in fasting (only food was with held) for 12 hrs and 
weighed prior to dosing. Three animals were used for each step. A single dose of the 
solution (2ml/kg) was consecutively administered by oral gavage using intubation 
cannula. Food was with held for another 4 hrs after dosing and administration of drug. 
As per the guide line the starting dose level was taken as 2ml/kg body weight.  
 
Observations:  
 Observations were made and recorded systematically and continuously observed 
after the substance administration as per the guidelines.  
 ½ hour, 1 hour, 2 hours, 4 hours and up to 24 hours observation  
 All rat were observed twice daily on week days for 14 days  
 Body weight was weighted once in a week 
 Feeded once a day  
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 Cage side observation : 
The animals were monitored for behavioral parameters like, Alertness, 
Aggressiveness, pilo erection, Grooming, Gripping, Touch Response, Motor Activity, 
Tremors, Convulsions, Muscle Spasm, Catatonia, Muscle relaxant, Hypnosis Analgesia, 
Lacrimation, Exophthalmos, Diarrhea, Writhing,  Respiration, Mortality  
Necropsy:  
Necropsy was done and gross examinations of the external surface of the body, 
all orifices, cranial, thoracic and abdominal cavities and their contents. Brain, eyes,  
lungs, heart, spleen, liver, kidneys, adrenals, uterus of all animals were observed and 
noted.  
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CLINICAL STUDY 
STUDY TYPE  :                           
An open clinical trial  
 
STUDY PLACE                              
OPD & IPD of Ayothidass pandithar, hospital,  
National Institute of Siddha, Chennai-47  
 
STUDY PERIOD                         
             18 months 
 
SAMPLE SIZE                            
              30 children (Both in IPD and OPD )  
  
SUBJECT SELECTION:  
Children with symptoms of Baala Vatham was subjected to screening by 
screening Profoma. After screening they were enrolled for the study fulfilling the 
inclusion criteria as said below: 
 
INCLUSION CRETERIA: 
1.Children of age group under 2-12 years   
2. Mono/Para/ Hemi/Tri/Double/Tetra/Quadri paresis  
 3. Weakness of one or more limbs   
4.  Loss of power and tone in muscles of the affected limb    
5. Difficulty/ Inability in using the affected limb against gravity and resistance   
 6. Difficulty in using the affected limb  
 
EXCLUSION CRETERIA:   
1. H/o Epilepsy    
2. Severe Aggressiveness with ADHD    
3. Autism    
4. H/o Cerebral palsy    
5. Congenital Heart Disease    
6.  Any other serious illness    
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WITHDRAWL CRITERIA:  
 Intolerance to the drug and development of adverse reactions during drug 
trial.  
 Poor patient compliance and defaulters.  
 Patient turning unwilling to continue in the course of clinical trial.  
 Occurrence of any other systemic illness  
 
TESTS AND ASSESMENTS  
A. Clinical assessment  
 B. Siddha investigations  
C. Modern aspects 
 
A.CLINICAL ASSESMENT  
1) Baala Vatham involving in one or more limbs 
2) Weakness of the affected limb 
3) Loss of power and tone in muscles of the affected limb 
4) Difficulty/Inability in using the affected limb against gravity and resistance 
5) Difficulty in using the affected limb 
6) Muscle spasticity present in the affected limb 
 
B. SIDDHA SYSTEM EXAMINATION:  
1) Naadi  
2) Sparisam  
3) Naa  
4) Niram  
5) Mozhi  
6) Vizhi  
7) Malam                
8) Moothiram a. Neer kuri: b. Nei Kuri:  
 
C. MODERN ASPECT 
1) Bulk of the muscle  
2) Muscle tone 
3) Muscle power 
4) Reflexes   
5) Aswarthscale 
6) Modefied aswath saale 
  
 67  
DATA COLLECTION FORMS: 
 
Required information will be collected from each patient by using following 
forms. 
 
1. Screening form (Form I) 
2. Consent form (Form II) 
3.Information sheet (Form III) 
4. Assent form (Form IV) 
5.Case report form (CRF) (Form V) 
6.Drug compliance (Form VI) 
7.Withdrawl (Form VII) 
8.Adverse reaction ( Form VIII) 
9.Pharmaco vigilance form (Form IX) 
10.Dietary advice form (Form X) 
 
 STUDY ENROLLMENT  
Child visited the OPD of NIS with the clinical symptoms of BAALA 
VAATHAM was examined clinically. Based on the inclusion and exclusion criteria, they 
are enrolled for the study.  
 
The Children who are going to be enrolled would be informed about the study, 
trial drug, possible outcomes and the objectives of the study in their vernacular language. 
After ascertaining the consent from their parents, informed consent would be obtained in 
written form..  Before enrolling the children the parents were informed about the study, 
trial drug, possible outcomes and the objectives of the study in their vernacular language. 
And got consent from their parents, informed consent was received in written form. 
All these children were given unique registration card in which patient’s 
Registration number of the study, Address, Phone number and Doctors phone number 
etc. was given, so as to report any complications. 
Complete clinical history, complaints and duration, examination findings was 
recorded in the prescribed Proformas. Parents was advised to give the trial drug to the 
children with appropriate dietary advice.  
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CONDUCT OF THE STUDY:  
The trial drug Chitra mutti kudineer chooranam (Internal) and Baala Vaatha 
thylam (External) is given for 45 days. OPD patients are adviced to visit the hospital 
once in 7 days. At each clinical visit prognosis was noted. For IPD patients the clinical 
assessment was done daily with the supervision of the faculty members in the Ward.  
The results was compared at the end of the study. At the end of the treatment, the parents 
was advised to visit the OPD along with their children for follow-up for  observing any 
recurrence. Defaulters was not allowed to continue and was withdrawn from the study.  
DATA ANALYSIS:  
 After enrolling the children in the study, a separate file was maintained for each 
and every children and all forms and other information was kept in the file. The 
screening forms was filed separately.  The data entry was monitored by the Head of the 
department and faculties of the concerned department. All collected datas was 
statistically analysed by Senior Research Officer (Statistics) for logical errors and 
incompleteness of data to avoid bias.   
ADVERSE EFFECTS/SERIOUS EFFECTS MANAGEMENT:  
In this Study no adverse reactions Were observed during the course of treatment  
OUTCOME OF THE RESULT: 
The outcome of the result was assessed by Spasticity assessment scale  
(MODIFIED ASWORTH SCALE) before and after treatment.  Paresis children are 
assessed by bulk of the muscle, muscle power, muscle tone, reflex, asworth scale and 
modified asworth scale.  
OUTCOM E: 
Bulk of the muscle : By measuring method 
Normal nutrition\ Abnormal 
Tone of the muscle: by Shaking the limb 
 Normal/ Hypertonia / Hypotonia 
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Power of the Muscle:  
Upper limb and lower limb- Based on MCR grading 
   Grade 0 – Complete paralysis total paralysis (no power) 
   Grade 1 – Visible or palpable flicker or trace of contracture, not enough to move a joint 
   Grade 2 – Able to move eliminating the gravity 
   Grade 3 – Able to move against gravity but not against resistance 
   Grade 4 – Able to move against partial resistance 
   Grade 5 – Normal power 
 
Reflex of the Muscles:  
      Superficial reflex :  
  Present/Absent 
      Deep tendon reflex: by grading 
Grade 0 - Absent 
Grade 1 – Sluggish, obtainable with reinforcement 
Grade 2 – Readily electable, normal (like normal ankle jerk) 
Grade 3 – Brisk/increased (like normal knee jerk) 
Grade 4 – Exaggerated/associated with clonus (sustained/ill-substained) 
 
Spasticity assessment : by using the Ashworth & Modified Ashworth scales 
The Ashworth scale to assess the spastic paresis: 
 Grade 0 -   No increase in tone  
 Grade 1 – Slightly increase in tone giving a catch when the limb is moved in 
flexion or extension  
 Grade 2 – More marked increase in tone but limb easily flexed  
 Grade 3 – Considerable increase in tone passive movements is difficult 
 Grade 4 – limb rigid in flexion or extension 
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The Modified Ashworth scale: 
 Grade 0  -  No increase in tone – Score 4 
 
Grade 1 – Slightly increase in muscle tone, manifested by a catch and release or 
by minimal resistance at the end of the ROM  when the affected part(s) is moved in 
flexion or in extension – Score 3 
  Grade1+ slightly increase in muscle tone, manifested by a catch, followed by 
minimal resistance throughout the remainder (less than half) of the ROM – Score 2.5 
 Grade 2 – More marked increased in muscle tone throughout most of the ROM, 
but affected part(s) easily moved – Score 2 
 Grade 3 – considerable increase in muscle tone, passive movements is difficult – 
Score 1 
 Grade 4 – Affected part(s) rigid in flexion or extension – Score 0 
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PRE CLINICAL STUDY  RESULTS AND OBSERVATIONS 
 
PHYSICOCHEMICAL ANALYSIS OF CHITRAMUTTI KUDIEER 
CHOORANAM 
 
S.No Parameters Percentage 
1. Loss on drying 5.37% 
2 Total ash value 4.32% 
3 Acid insoluble ash Less than 1% 
4 Water soluble ash 1.96% 
5 Water soluble extrction 10.63% 
5 Alcohol soluble etraction 16.4% 
 
Inferance: 
The Physiochemical analysiscarried out proves the percentage of Loss on drying, 
Total Ash value, Acid insoluble ash, Water soluble ash, Water soluble extraction, 
Alcohol soluble actions. 
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PRELIMINARY PHYTOCHEMICAL SCREENING CHITAMUTTI  
KUDINEER CHOORANAM 
The preliminary phytochemical studies of aueous extract of Chitramutti 
Kudineer Chooranam were done using standard procedures.  The present study reveals 
that the bioactive compounds were present in all the extracts of  Chitramutti Kudineer 
Chooranam. 
S.No Phytochemicals Test Name H2O Extract 
1.  
Alkaloids 
Mayer’s Test -ve 
Wagner’s Test -ve 
Dragendroff’s Test -ve 
Hager’s Test -ve 
2. Carbohydrates Molish’s Test +ve 
Benedict’s Test +ve 
3. Glycoside Modified Borntrager’s test -ve 
Keller killiani -ve 
4. Saponin Forth test +ve 
Foam Test -ve 
5. Phytosterol Salkowski’s Test -ve 
6. Phenols Ferric Chloride Test -ve 
7. Tannins Gelatin test -ve 
8. Flavnoids Alkaline Reagent Test +ve 
Lead acetate Test +ve 
9. Protenis and amino acids Xanthoprotetic Test -ve 
10. Diterpenes Copper Acetate test +ve 
11. Gum & mucilage Extract + Alc0hol -ve 
12. Fat & Fixed oil Spot Test -ve 
13. Quinones NAOH + Extract +ve 
 
+ ve/- ve Present or absent if component  tested. 
Inferance: 
 
The preliminary phytochemical analysis for basic phytochemical reveals that 
Chittramutti kudineer Chooranam contains Carbohydrates, Saponins, Flavanoids, 
Diterpenes, Quinones. 
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BIO CHEMICAL ANALYSIS 
 Colour, Nature of Chittra mutti kudineer Chooranam 
S.no Parameters Results Method of Testing 
1. Colour Yellowish green By visual 
2. Odour Odour(Omam Smell) Olfactory examination 
3. Solublity Completely soluble Qualitative 
4. Nature Powder By visual 
  
Inferance: 
  The biochemical analysis of Chitra Mutti Kudineer  appears yellowish green in 
color by the visual method, and its odour like as a Omam smell by olfactory examination 
method, Completely soluble in  the qualitative method, Nature of power determine by the 
visual method. 
 
Test for Basic radicals 
S.no Procedures Chitra mutti kudineer 
Chooranam 
1. Test for Ammonium - 
2. Test for Sodium - 
3. Test for Magnesium - 
4. Test for Aluminium - 
5. Test for Potassium + 
6. Test for Calcium - 
7. Test for Ferrous iron + 
8. Test for Copper - 
9. Test for Zinc - 
10. Test for Arsenic - 
11. Test for Mercury - 
12. Test for Lead - 
Inference 
Bio-chemical analysis for basic radicals reveals that Chittramutti 
kudineer Chooranam contains Potassium, and Iron. 
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Test for Acidic radicals 
S.No Procedures 
Chitra Mutti Kudineer 
Chooranam 
1. Test for Sulphate - 
2. Test for Chloride + 
3. Test for Phosphate + 
4. Test for Flouride & Oxalate - 
5. Test for Nitrate _ 
 
Inferance: 
Bio-chemical analysis for Acid radicals reveals that Chittramutti kudineer 
Chooranam contains chloride, phosphate. 
Test for Acidic radicals 
S.no Procedures 
Chittra mutti kudineer 
Chooranam 
1. Test for Starch - 
2. Test for Reducing sugar - 
3. Test for Alkaloids + 
4. Test for Amino acids _ 
5. Test for Tannic acids + 
6. Test for type of compounds No Change 
Inference 
Bio-chemical analysis for acid radicals reveals that Chittra mutti Chooranam 
contains Chloride, phosphate, Alkaloids, Tannic acids 
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TOXICITY STUDY 
RESULTS OF CHITTRA MUTTI KUDINEER DOSE FINDING EXPERIMENT 
AND ITS BEHAVIOURAL SIGNS OF TOXICITY 
No Dose 
ml/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1. Control + + + + + + + + + + + + + + + + + + + + 
2. 2ml + + + + + + + + + + + + + + + + + + + + 
1.Alertness 2.Aggressiveness 3.pilo erection 4.Grooming 5.Gripping 6.Touch 
Response 7.Motor Activity 8. Tremors 9.Convulsions 10.Muscle Spasm 11.Catatonia 
12.Muscle relaxant 13.Hypnosis 14.Analgesia 15.Lacrimation 16.Exophthalmos 
17.Diarrhoea 18.Writhing 19. Respiration 20.Mortality 
+ Presence of Activity 
- Absence of Activity 
2ml- 2.7ml in the consentrated state  
 
All the data were summarized in the form of table revealed no abnormal signs 
and behavioural changes in rats at the dose of 2 ml/kg body weight administered 
orally. 
 
Acute Toxicity study 
In acute toxicity study, the test drug at Chittra mutti Kudineer for single dose 
(2ml/kg b.wt) was administered. 
There was no mortality or signs of toxicity observed after dosing Chittra mutti 
Kudineer 2ml/kg body weight during the study period of 14 days. This indicate that the 
LD50 of Chittra mutti Kudineer is more then 2ml/kg b.wt. 
There was no changes in skin and fur, eyes and mucous membranes of all 
animals. The eating, drinking habit, sleep pattern, locomotion were normal in all 
animals and no changes in body weight as compared to control group. 
At the end of the 14 
th
 day necropsy was done and there was no abnormality 
seen in test groups as compared to control group during the examination. 
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CLINICAL OBSERVATIONS AND RESULTS 
Results of the study were observed with respect to the following criteria  
   1. Sex Distribution  
  2.  Age Distribution 
   3. Socio-Economical Status  
   4. Diet  
   5. Thinai  
   6. Paruva kaalam  
   8. Gunam  
   9. Body Constitution  
   10. Naadi  
   11. Distribution of Vali    
   12. Distribution of Azhal  
   13. Distribution of Iyam  
   14. Envagai thervugal  
   15. Neikkuri  
   16. Udhal thaathukkal  
   17. Kanmenthiriyam  
   18. Cranial Nerve Examination  
   19.  Classification of paresis based on the affected limb 
   20. Bulk of the Muscle 
   21. Muscle tone 
   22. Muscle power 
 I. Grade of the upper limb power 
 II. Grade of the lower limb power 
   23. Reflex 
 I Superficial reflex 
  II. Deep tendon reflex 
Before treatment 
After treatment 
24. Assessment scales Asworth and modified Asworth scale 
25. Result assessment by modified Asworth scale before and after treatment 
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CLINICAL OBSERVATION AND RESULT 
 
 1. SEX  DISTRIBUTION :  
S. No Sex No.  Of cases Percentage 
1. Male child 16 53.3% 
2. Female child 14 46.6% 
 
 
 
Observation : 
From this study, the  affected gender of the disease was found to be high in male 
gender.  Among 30 children 53.3% males and 46.6%females was affected . 
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2. AGE DISTRIBUTION: 
S. No Age No of cases Percentage 
1. 2-5Years 17 56.6% 
2. 6-9Years 10 38.3% 
3. 10-12Years 3 10% 
 
 
 
Observation:  
In this study, 56.6 % of children came under the age group between 2-5 years, 
38.3% of children were under the age of 6-9 years, 10 % of children were between 10-12 
years. 
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3. SOCIO ECONOMIC STATE: 
S. No Socio economic state No. of cases Percentage 
1. Upper 1 3.3% 
2. Upper middle 11 36.6% 
3. Lower middle 8 26.6% 
4. Upper lower 8 26.6% 
5. Lower 2 6.6% 
    
 
 
Observation:   
In this study, based on the socio economic state, 36.6% come under upper middle 
class , 26.6% were lower middle and upper middle level income group, 6.6%  were  from  
lower  level income group and 3.3% were from upper level income group.  
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4.DIET: 
S. No Dietary Habit No of Cases Percentage 
1. Non vegetarian 26 86.6% 
2. Vegetarian 4 13.3% 
 
] 
Observation :    
Among 30 children, 86.6% of patients non vegetarian and 13.3% of patients were 
vegetarian. 
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5. THINAI: 
S. No Thinai No of cases Percentage 
1. Kuruinji (Hill area) 2 6.6% 
2. Mullai (Forest area) - - 
3. Marutham (Fertil land) 5 16.6% 
4. Neithal (Coastal area) 23 76.6% 
5. Paalai (Desart land) - - 
 
 
Observation:   
  Among the 30 children, 76.6% of children from Neithal thinai, 16.6% of children  
from  Marutham  and 6.6%  from Kuruinji thinai. 
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7. PARUVA KAALAM : 
S. No Kaalam No of cases Percentage 
1. Kaarkaalam 1 3.3% 
2 Koothirkaalam 3 10% 
3 Munpanikaalam 12 40% 
4. Pinpanikaalam 6 20% 
5. Illavenilkaalam 6 20%% 
6. Muthuvenilkaalam 2 6.6% 
 
 
 
 
Observation:  
 Out of 30 children, 40% of the children were treated in Munpani kaalam, 20% of 
them in Pinpani kaalam, 20% in illavenir kalam, 6.6% children were treat in Muthuvenil 
kalam and the remaining 3.3%  in Kaarkalam.  
  
 
 83  
0
5
10
15
20
25
Sathuvagunam Rasogunam Thamogunam
3
25
2
10%
83.30%
6.60%
No of cases
Percentage
8.GUNAM: 
S.No Gunam No of cases Percentage 
1 Sathuvagunam 3 10% 
2 Rasogunam 25 83.3% 
3 Thamogunam 2 6.6% 
    
    
Observation:  
  In 30 children, 83.3 cases cunder Rasogunam, 10% under Sathuva Gunam, 6.6% 
under Thamogunam.    
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9.YAKKAI ILAKKANAM (BODY CONSTITITUTION): 
S.No Yakkaiilakkanam No of cases Percentage 
1 Vaathathegi - - 
2 Pithathegi - - 
3 Kabathegi - - 
4 Thonthathegi 30 100% 
 
 
Observation: 
Among 30 children,  all of them came under  thontha thegi. 
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10. DISTURBANCE OF VAATHAM: 
S. No Vaatham No of cases Percentage 
1 Pranan - - 
2 Abanan 6 20% 
3 Viyanan 30 100% 
4 Uthanan - - 
5 Samanan 30 100% 
6 Nagan - - 
7 Koorman 3 10% 
8 Kirugaran - - 
9 Devathathan - - 
10 Dhananjeyan - - 
 
 
Obervation: 
 In Vaatham, Viyaanan and Samanan affected in all the 30 children (100%), In 
6% children Abaanan affected and in 10% of children  koorman  was affected.  
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11. DISTURBANCE OFAZHAL: 
S.No Pitham No of Cases Percentage 
1 Anarpitham 6 20% 
2 Ranjagapitham 30 100% 
3 Sathaga pitham 30 100% 
4 Alosagapitham - - 
5 Prasaga pitham - - 
 
 
Observation: 
  In Pitham, Anar pitham was affected in 20% of cases, Ranjagapitham and 
Saathagam  affected in  all the 100%  of cases.  
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12. DISTURBANCE OF IYAM: 
S.No Iyam No of Cases Percentage 
1 Avalambagam 30 100% 
2 Kilethagam - - 
3 Pothagam - - 
4 Tharpagam -  
5 Santhigam 30 100% 
 
 
Observation:  
Among the 30 cases, Avalambagam and Santhigam affected in all the 30 cases.  
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13. ENVAGAI THERVUGAL: 
S.No Envagai thervugal No of cases Percentage 
1 Naadi 
  Vathapitham 12 40% 
 Pithavatham 10 33.3% 
 Kabavatham 4 13.3% 
 Kabapitham 6 20% 
2 Sparisam 30 100% 
3 Naa - - 
4 Niram - - 
5 Mozhi 2 6.6% 
6 Vizhi 2 6.6% 
7 Malam 6 20% 
8 Moothiram - - 
 
Observation: 
 In Envagaithervugal, Sparisam was affected in all the 30 cases. The Naadi in 
Baala Vaatham was recorede as 40% with Vathapitham, 10% pithavatham, 4% Kaba 
Vatham, 6% which Kabapitham. 
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14. NEIKKURI: 
S.No Neikuri No of cases Percentage 
1 Vaathaneer(Aravena neendathu) 8 26.6% 
2 Pithaneer (Azhipol paraviyathu) 5 17% 
3 Kaba Neer (Muthothu nindrathU) 17 56.6% 
4 Others - - 
  
 
Obsevation: 
  Among 30 cases,  in 8  cases(26.6%) was found to be with Vaatha neer, 5 cases 
(17%) with pita neer, and17cases (56.6%) With kaba neer. 
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15. UDAL THAATHUKKAL: 
S.No Udalthaathukkal No of cases Percentage 
1 Saaram 30 100% 
2 Senneer 30 100% 
3 Oon 30 100% 
4 Kozhuppu 20 66.6% 
5 Enbu - - 
6 Moolai - - 
7 Sukkilam\ 
suronitham 
- - 
 
 
Observation : 
In this study, Saaram, Senneer and Oon were affected in all the 30 cases (100%). 
Kozhuppu was affected in 20 cases (66.6%) 
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16. KANMENTHIRIYAM: 
S.No Kanmenthiriyam No of cases Percentage 
1 Kai 15 50% 
2 Kaal 28 93.3% 
3 Vaai - - 
4 Eruvai - - 
5 Karuvai - - 
 
 
Observation:   
In Kanmendrium, Kai was affected in 15 cases (50% ) and Kaal was affected in 
28 cases (93.3%). 
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17.CRANIAL NERVE EXAMINATION: 
 
 
Observation: 
During cranial nerve examination 2 children showed abnormality in optic, 
trigeminal, facial and spinal accessory nerves and one child shows abnormality in 
glossopharyngeal nerve and Vestibulo cocclear nerve. 
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Before treatment
After treatment
S.No Cranial Nerve 
Before treatment no 
of cases 
After treatment no of 
cases 
1. Olfactory - - 
2. Optic - - 
3. Oculomotor 2 2 
4. Trochelar - - 
5. Trigeminal 2 2 
6. Abducent - - 
7. Facial 2 2 
8. Vestibulo cochlear 1 1 
9. Glassopharyngel 1 - 
10. Vagus - - 
11. Spinal accessory 2 2 
12. Hypoglossal - - 
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18. CLASSIFICATION OF PARESIS BASED ON AFFECTED LIMB: 
 
S. No Paresis No of cases Percentage 
1 Mono paresis 4 13.3% 
2 Para paresis 12 40% 
3 Hemi paresis 10 33.3% 
4 Tri pareisis 1 3.3% 
5 Double hemiparesis - - 
6 Tetra paresis - - 
7 Quadri paresis 3 10% 
 
 
Observation: 
Among 30 cases 40% of the cases were recorded as para paresis, 33.3% as Hemi 
paresis, 13.3% as Mono paresis 10% as Quadri paresis and remaining 3.3% as Triparesis. 
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19. BULK OF THE MUSCLE: 
S.No  
O.P/I.P No 
Before treatment After treatment 
Upperlimb Lower limb Upper 
limb 
Lower limb 
Rt Lt Rt Lt Rt Lt Rt Lt 
1. J35430 N N A A N N N N 
2. J12304 A A A A N N N N 
3. J32268 N N N N N N N N 
4. J73325/0153-17 A A A A A A A A 
5. J73308/0197-17 A N A N N N N N 
6. J77120/033-18 N N A A N N N N 
7. J73621/ 0230-17 A N A N A N A N 
8. I75399 N N N N N N N N 
9. J83360 N N N N N N N N 
10. J42382/0244-17 N A N A N N N N 
11. J94318/0184-18 N N A N N N N N 
12. J78239 N N N N N N N N 
13. J91230 N N A A N N N N 
14. J89415 N N A A N N A A 
15. J57667/0290-18 N N A A N N N N 
16. F84077/0606-18 N A N A N A N A 
17. J97621 N N N N N N N N 
18. J97076 N N N N N N N N 
19 K03676/0431-18 A N A N N N N N 
20. K10779/0422-18 N N N N N N N N 
21. K10780/0423-18 N N N N N N N N 
22. K12603 A N A A N N N N 
23. E89125 A N N N N N N N 
24. K18069 N N A A N N N N 
25. I69163 A N A N N N N N 
26. J45333 A A A A A A A A 
27. J88827 N A N A N N N N 
28. K20331/0562-18 A N A N N N N N 
29. K18463/0512-18 N A N A N A N A 
30. J85220/0614-18 N A N A N A N A 
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Bulk of the 
Muscle 
Before treatment After treatment 
No. of cases percentage No of cases Percentage 
Normal 5 16.6% 23 76.6% 
Affected 25 83.3% 7 23.3% 
 
 
 
Observation: 
 Among  the 30 children, 5 ( 16.6% )children had a normal bulk of the ,muscle 
before the onset of treatment but they had difficulty  in using  the limbs and  the 
remaining 25 (83.3%)  were affected in the muscle bulk. After the course of treatment 
the 83.3%  affected children’s muscle bulk was gradually improved. 7 cases had no 
improvement in their muscle bulk. 
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20.MUSCLE TONE: 
S. No Muscle tone Before treatment After treatment 
No Percentage No Percentage 
1. Normal tone - - 28 93% 
2. Hyper tonia 30 100% 2 7% 
3. Hypo tonia - - - - 
 
Observation: 
 All the children were found have hyper tonia and after treatement the spasticity 
was reduced in 93% (28) of the children, remaing 7% (2) children spasticity was static.  
  
Obaservation: 
 30  hypertonic children were selected for the study, among them 28 children’s 
muscle tone  was  improved to the normal tonic stage during the treatment period and 
remaining 7 children had no improvement in their muscle tone. 
 
 
0%
100%
0%
93%
7%
0%
0%
20%
40%
60%
80%
100%
120%
Normal tone Hyper tonia Hypo tonia
P
e
r
c
e
n
t
a
g
e
Muscle tone
Before treatment
After treatment
 97  
21. MUSCLE POWER: 
S.No O.P/I.PNo Before treatment After treatment 
Upper limb Lower limb Upper limb Lower limb 
Pro Dis pro dis pro Dis Prox Dis 
1. J35430 G5 G5 G2 G2 G5 G5 G4 G4 
2. J12304 G2 G2 G2 G2 G4 G4 G4 G4 
3. J32268 G2 G3 G5 G5 G4 G5 G5 G5 
4. J73325/0153-17 G1 G1 G1 G1 G2 G2 G2 G2 
5. J73308/0197-17 G2 G2 G3 G2 G5 G5 G4 G5 
6. J77120/033-18 G5 G5 G3 G2 G5 G5 G5 G5 
7. J73621/ 0230-17 G3 G3 G3 G3 G5 G5 G5 G5 
8. I75399 G5 G5 G3 G3 G5 G5 G5 G5 
9. J83360 G5 G5 G3 G3 G5 G5 G5 G5 
10. J42382/0244-17 G2 G1 G2 G2 G4 G4 G4 G4 
11. J94318/0184-18 G5 G5 G2 G2 G5 G5 G4 G4 
12. J78239 G5 G5 G3 G3 G5 G5 G5 G5 
13. J91230 G5 G5 G2 G3 G5 G5 G4 G4 
14. J89415 G5 G5 G3 G3 G5 G5 G5 G5 
15. J57667/0290-18 G5 G5 G1 G1 G5 G5 G4 G4 
16. F84077/0606/18 G2 G2 G2 G2 G4 G4 G4 G4 
17. J97621 G5 G5 G3 G3 G5 G5 G5 G5 
18. J97076 G3 G3 G5 G5 G4 G4 G5 G5 
19. K03676/0431-18 G2 G2 G2 G2 G4 G4 G4 G4 
20. K10779/0422-18 G5 G5 G3 G3 G5 G5 G4 G4 
21. K10780/0423-18 G5 G5 G3 G3 G5 G5 G4 G4 
22. K12603 G3 G3 G2 G2 G5 G5 G4 G4 
23. E89125 G3 G2 G5 G5 G4 G4 G5 G5 
24. K18069 G5 G5 G3 G2 G5 G5 G5 G5 
25. I69163 G2 G2 G1 G1 G4 G4 G4 G4 
26. J45333 G2 G2 G2 G2 G2 G2 G2 G2 
27. J88827 G3 G3 G3 G3 G5 G5 G5 G5 
28. K20331/0562 -18 G3 G3 G3 G3 G5 G5 G5 G5 
29. K18463/0512- 18 G2 G2 G2 G2 G3 G3 G3 G3 
30. J85220/0614-18 G2 G2 G2 G3 G3 G3 G3 G3 
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Grade 0 – Complete paralysis, total paralysis (no power) 
Grade 1 – Visible or palpable flicker or trace of contracture, not enough to move a joint 
Grade 2 – Able to move eliminating the gravity 
Grade 3 – Able to move against gravity but not against resistance 
Grade 4 – Able to move against partial resistance 
Grade 5 – Normal power 
  
21. I.GRADING OF UPPER LIMB POWER: 
S.No Grading Before treatment After treatment 
Upper limb Upper limb 
Proximal Distal Proximal Distal 
No % No % no % No % 
1. Grade 0 - - - - - - - - 
2. Grade 1 1 3% 2 6% - - - - 
3. Grade 2 10 33.3% 9 30% 2 6% 2 6% 
4. Grade 3 6 20% 6 20% 2 6% 2 6% 
5. Grade 4 - - - - 8 26.6 7 23.3% 
6. Grade 5 13 43.3% 13 43.3% 18 60% 19 63.3% 
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21. II.GRADING OF LOWER LIMB POWER : 
S.No 
 
 
Grading 
Before treatment After treatment 
Lower limb Lower limb 
Proximal Distal Proximal Distal 
No % no % no % No % 
1. Grade 0 - - - - - - - - 
2. 
Grade 1 3 10% 3 10% - - 
 
- - 
3. Grade 2 11 36.6%% 12 40% 2 6.6% 2 6% 
4. Grade 3 13 43.3% 12 40% 2 6.6% 2 6% 
5. Grade 4 - - - - 13 43.3% 12 40% 
6. Grade 5 3 10% 3 10% 13 43.3% 14 46.6% 
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22. SUPERFICIAL REFLEX: 
S. No Op.I.P No Before treatment After treatment 
1. J35430 + + 
2. J12304 - + 
3. J32268 + + 
4. J73325/0153-17 - - 
5. J73308/0197-17 + + 
6. J77120/033-18 + + 
7. J73621/ 0230-17 + + 
8. I75399 + + 
9. J83360 + + 
10. J42382/0244-17 + + 
11. J94318/0184-18 + + 
12. J78239 + + 
13. J91230 + + 
14. J89415 + + 
15. J57667/0290-18 + + 
16. F84077/0606/18 + + 
17. J97621 + + 
18. J97076 + + 
19. K03676/0431-18 + + 
20. K10779/0422-18 + + 
21. K10780/0423-18 + + 
22. K12603 + + 
23. E89125 + + 
24. K18069 + + 
25. I69163 + + 
26. J45333 - - 
27. J88827 + + 
28. K20331/ 0562 -18 + + 
29. K18463/0512 -18 + + 
30. J85220/0614-18 + + 
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S. No Superficial reflex 
Before treatment After treatment 
No Percentage No Percentage 
1. Postivie  superficial 
reflex 
27 90% 28 93.3% 
2. Absent of superficial 
reflex 
3 10% 2 6.6% 
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22.I.DEEP TENDON REFLEX BEFORE TREATMNT: 
S.No O.P./I.P.No Before treatment 
 
Ja
w 
 
Bi Tri Sup Knee Angle 
R L R L R L R 
 
L 
 
R L 
1. J35430 ++ ++ ++ ++ ++ ++ ++ ++++ ++++ +++ +++ 
2. J12304 ++ +++ +++ +++ +++ +++ +++ ++++ ++++ +++ +++ 
3. J32268 ++ +++ ++ +++ ++ +++ ++ +++ +++ ++ ++ 
4. J73325/0153-17 ++ +++ +++ ++++ +++ +++ +++ ++++ ++++ +++ +++ 
5. J73308/0197-17 ++ +++ ++ +++ ++ +++ ++ ++++ +++ +++ ++ 
6. J77120/033-18 ++ ++ ++ ++ ++ ++ ++ ++++ ++++ +++ +++ 
7. J73621/ 0230-17 ++ +++ +++ +++ +++ +++ +++ ++++ ++++ +++ +++ 
8. I75399 ++ +++ +++ ++++ +++ +++ +++ +++ +++ ++ ++ 
9. J83360 ++ ++ ++ ++ ++ ++ ++ ++++ +++ +++ ++ 
10. J42382/0244-17 ++ ++ +++ ++ +++ ++ +++ +++ ++++ ++++ ++++ 
11. J94318/0184-18 ++ ++ ++ ++ ++ ++ ++ ++++ +++ +++ +++ 
12. J78239 ++ ++ ++ ++ ++ ++ ++ ++++ ++++ +++ +++ 
13. J91230 ++ ++ ++ ++ ++ ++ ++ ++++ +++ +++ +++ 
14. J89415 ++ ++ ++ ++ ++ ++ ++ ++++ ++++ +++ +++ 
15. J57667/0290-18 ++ ++ ++ ++ ++ ++ ++ ++++ ++++ ++++ ++++ 
16. F84077/0606/18 ++ ++ +++ ++ +++ ++ +++ +++ ++++ ++ +++ 
17. J97621 ++ ++ ++ ++ ++ ++ ++ ++++ ++++ +++ +++ 
18. J97076 ++ +++ +++ +++ +++ +++ +++ +++ +++ ++ ++ 
19. K03676/0431-18 ++ +++ ++ +++ ++ +++ ++ ++++ +++ +++ ++ 
20. K10779/0422-18 ++ ++ ++ ++ ++ ++ ++ ++++ ++++ ++++ ++++ 
21. K10780/0423-18 ++ ++ ++ ++ ++ ++ ++ ++++ ++++ +++ ++++ 
22. K12603 ++ +++ ++ +++ ++ +++ ++ ++++ ++++ +++ +++ 
23. E89125 ++ +++ ++ +++ ++ +++ ++ +++ +++ ++ ++ 
24. K18069 ++ ++ ++ ++ ++ ++ ++ ++++ ++++ +++ +++ 
25. I69163 ++ ++++ ++ ++++ ++ ++++ ++ ++++ +++ ++++ ++ 
26. J45333 ++ +++ +++ +++ +++ +++ +++ ++++ ++++ +++ +++ 
27. J88827 ++ ++ ++++ ++ ++++ ++ ++++ +++ ++++ ++++ ++++ 
28. K20331/ 0561 -18 ++ +++ ++ +++ ++ +++ ++ ++++ +++ +++ ++ 
29. K18463/0512 -18 ++ ++ ++++ ++ ++++ ++ ++++ +++ ++++ ++ ++++ 
30. J85220/0614-18 ++ ++ ++++ ++ ++++ ++ ++++ +++ ++++ ++ ++++ 
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22. II.DEEP TENDON REFLEXES BEFORE TREATMEN: 
S.No Grade Jaw 
jerk 
Biceps Triceps Supinator Knee Ankle 
R L R L R L R L R L 
1. Grade 0 - - - - - - - - - - - 
2. Grade 1 - - - - - - - - - - - 
3. Grade 2 30 17 19 17 19 17 19 - - 7 9 
4. Grade 3 - 12 8 10 8 12 8 10 11 18 13 
5 Grade 4 - 1 3 3 3 1 3 20 19 5 8 
 
23. I. DEEP TENDON REFLEX AFTER TREATMENT: 
S.
No 
O.P./I.P.No 
After treatment 
Ja
w 
Bi Tri Sup Knee Angle 
R L R L R L R L R L 
1. J35430 ++ ++ ++ ++ ++ ++ ++ +++ +++ ++ +++ 
2. J12304 ++ +++ +++ ++ +++ +++ +++ ++++ ++++ +++ +++ 
3. J32268 ++ +++ ++ +++ ++ +++ ++ +++ +++ ++ ++ 
4. J73325/0153-17 ++ +++ +++ +++ +++ +++ +++ ++++ ++++ +++ +++ 
5. J73308/0197-17 ++ ++ ++ ++ ++ ++ ++ +++ +++ ++ ++ 
6. J77120/033-18 ++ ++ ++ ++ ++ ++ ++ +++ +++ ++ ++ 
7. J73621/ 0230-17 ++ +++ ++ ++ ++ +++ ++ ++++ ++++ ++ ++ 
8. I75399 ++ ++ ++ ++ ++ ++ ++ +++ +++ ++ ++ 
9. J83360 ++ ++ ++ ++ ++ ++ ++ +++ +++ ++ ++ 
10. J42382/0244-17 ++ ++ ++++ ++ ++++ ++ ++++ +++ ++++ ++ ++++ 
11. J94318/0184-18 ++ ++ ++ ++ ++ ++ ++ +++ +++ ++ ++ 
12. J78239 ++ ++ ++ ++ ++ ++ ++ +++ +++ ++ +++ 
13. J91230 ++ ++ ++ ++ ++ ++ ++ +++ +++ ++ ++ 
14. J89415 ++ ++ ++ ++ ++ ++ ++ +++ +++ ++ ++ 
15. J57667/0290-18 ++ ++ ++ ++ ++ ++ ++ +++ +++ +++ +++ 
16. F84077/0606/18 ++ ++ +++ ++ +++ ++ +++ +++ ++++ ++ +++ 
17. J97621 ++ ++ ++ ++ ++ ++ ++ +++ +++ ++ ++ 
18. J97076 ++ ++ ++ ++ ++ ++ ++ +++ +++ ++ ++ 
19. K03676/0431-18 ++ ++ ++ ++ ++ ++ ++ +++ +++ ++ ++ 
20. K10779/0422-18 ++ ++ ++ ++ ++ ++ ++ ++++ ++++ +++ +++ 
21. K10780/0423-18 ++ ++ ++ ++ ++ ++ ++ +++ +++ ++ ++ 
22. K12603 ++ ++ ++ ++ ++ ++ ++ +++ +++ ++ ++ 
23. E89125 ++ ++ ++ ++ ++ ++ ++ +++ +++ ++ ++ 
24. K18069 ++ ++ ++ ++ ++ ++ ++ +++ +++ ++ ++ 
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S.
No 
O.P./I.P.No 
After treatment 
Ja
w 
Bi Tri Sup Knee Angle 
R L R L R L R L R L 
25. I69163 ++ +++ ++ +++ ++ +++ ++ +++ +++ +++ ++ 
26. J4533 ++ +++ +++ +++ +++ +++ +++ ++++ ++++ +++ +++ 
27. J88827 ++ ++ +++ ++ +++ ++ +++ +++ +++ +++ +++ 
28. K20331/ 0562 – 18 ++ ++ ++ ++ ++ ++ ++ +++ +++ ++ ++ 
29. K18463/ 0512 -18 ++ ++ ++++ ++ ++++ ++ ++++ +++ ++++ ++ ++++ 
30. J85220/0614-18 ++ ++ ++++ ++ ++++ ++ ++++ +++ ++++ ++ ++++ 
 
23. II.DEEP TENDON REFLEXES AFTER TREATMEN: 
S.No Grade 
Jaw 
jerk 
Biceps Triceps Supinator Knee Ankle 
R L R L R L R L R L 
1. Grade 0 - - - - - - - - - - - 
2. Grade 1 - - - - - - - - - - - 
3. Grade 2 30 24 22 26 22 24 22 - - 23 18 
4. Grade 3 - 6 5 4 5 6 5 25 21 7 9 
5 Grade 4 - - 3 - 3 - 3 5 9 - 3 
 
Grade 0 – Absent (-) 
Grade 1 – Sluggish, obtainable with reinforcement (+) 
Grade 2 – Readily electable, normal (like normal ankle jerk) (++) 
Grade 3 – Brisk/increased (like normal knee jerk (+++) 
Grade 4 – Exaggerated/associated with clonus (sustained/ill-substained) (++++) 
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BICEPS: 
Grade Before treatment After treatment 
Right Left Right Left 
No of 
cases 
Percent No of 
cases 
Percent No of 
cases 
Percent No of 
cases 
Percent 
Grade 0 - - - - - - - - 
Grade 1 - - - - - - - - 
Grade2 17 56.6% 19 63.3% 24 80% 22 73.3% 
Grade 3 12 40% 8 26.6% 6 20% 5 16.6% 
Grade 4 1 3.3% 3 10% - - 3 10% 
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TRICEPS: 
Grade Before treatment After treatment 
Right Left Right Left 
No of 
cases 
Percent No of 
cases 
Percent No of 
cases 
Percent No of 
cases 
Percent 
Grade 0 - - -      
Grade 1 - -       
Grade2 17 56.6% 19 63.3% 26 86.6% 22 73.3% 
Grade 3 10 33.3% 8 26.6% 4 13.3% 5 16.6% 
Grade 4 3 10% 3 10% - - 3 10% 
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SUPINATOR: 
Grade Before treatment After treatment 
Right Left Right Left 
No of 
cases 
Percent No of 
cases 
Percent No of 
cases 
Percent No of 
cases 
Percent 
Grade 0 - - - - - - -  
Grade 1 -  - - - - -  
Grade2 17 56.6% 19 63.3% 24 80% 22 73.3% 
Grade 3 12 40% 8 26.6% 6 20% 5 16.6% 
Grade 4 1 3.3% 3 10% - - 3 10% 
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KNEE JERK: 
Grade Before treatment After treatment 
Right Left Right Left 
No of 
cases 
Percent No of 
cases 
Percent No of 
cases 
Percent No of 
cases 
Percent 
Grade 0 - - - - - - -  
Grade 1 -  - - - - -  
Grade2 - - - - - - -  
Grade 3 10 33.3% 11 36.6% 25 83.3% 21 70% 
Grade 4 20 66.6% 19 63.3% 5 16.6% 9 30% 
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ANKLE JERK: 
Grade Before treatment After treatment 
Right Left Right Left 
No of 
cases 
Percent No of 
cases 
Percent No of 
cases 
Percent No of 
cases 
Percent 
Grade 0 - - -  -  -  
Grade 1 -  -  -  -  
Grade2 7 23.3% 9 30% 23 76.6% 18 60% 
Grade 3 18 60% 13 43.3% 7 23.3% 9 30% 
Grade 4 5 16.6% 8 26.6% - - 3 10% 
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24. ASSESSMENT SCALES 
 ASHWORTH AND MODIFIED ASHWORTH SCALE 
 
 S.No I.P/ O.P No Ashworth scale Modified Ashworth scale 
Before After Before After 
1 J35430 G3 G0 G3 G1 
2 J12304 G0 G0 G0 G0 
3 J32268 G3 G1 G3 G1+ 
4 J73325/0153-17 G0 G0 G0 G0 
5 J73308/0197-17 G3 G1 G3 G1+ 
6 J77120/033-18 G3 G1 G3 G1+ 
7 J73621/0230-17 G0 G0 G0 G0 
8 I75399 G2 G0 G2 G1 
9 J83360 G3 G1 G3 G1+ 
10 J42382/0244-17 G4 G2 G4 G2 
11 J94318/0184-18 G3 G1 G3 G1+ 
12 J78239 G2 G0 G2 G1 
13 J91230 G2 G0 G2 G1 
14 J89415 G2 G0 G2 G1 
15 J57667/0290-18 G3 G1 G3 G1+ 
16 F84077/0606-18 G3 G1 G3 G1+ 
17 J97621 G2 G0 G2 G1 
18 J97076 G2 G0 G2 G1 
19 K03676/0431-18 G3 G1 G3 G1+ 
20 K10779/0422-18 G2 G1 G2 G1+ 
21 K10780/0423-18 G2 G1 G2 G1+ 
22 K12603 G2 G0 G2 G1 
23 E89125 G2 G0 G2 G1 
24 K18069 G3 G1 G3 G1+ 
25 I69163 G4 G2 G4 G2 
26 J45333 G2 G0 G2 G1 
27 J88827 G3 G1 G3 G1+ 
28 K20331/ 0562-18 G2 G0 G2 G1 
29 K18463/0512-18 G3 G1 G3 G1+ 
30 J85220/0614-18 G4 G3 G4 G3 
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ASHWORTH SCALE: 
S. 
No 
 
Grading 
Before treatment After treatment 
No of cases Percentage% No of cases Percentage% 
1. Grade 0 3 10% 14 46.6% 
2 Grade 1 - - 13 43.3% 
3 Grade 2 12 40% 2 6.6% 
4 Grade 3 12 40% 1 3.3% 
5 Grade 4 3 10% - - 
 
MODEFIED ASHWORTH SCALE: 
S. No Grading Before treatment After treatment 
No of cases Percentage% No of cases Percentage% 
1. Grade 0 3 10% 3   10% 
2 Grade 1 - - 10 33.3% 
3 Grade 1+ - - 13 43.3% 
4 Grade 2 12 40% 2 6.6% 
5 Grade 3 12 40% 1 3.3% 
6 Grade 4 3 10% 1 3.3% 
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25. RESULTS BASD ON THE SPASTICITY ASSESSMENT (MODIFIED 
ASHWORTH ) 
 S.No 
I.P/ O.P No 
Modified Ashworth scale Grade with score 
Before After 
1 J35430 G3(1) G1 (3) 
2 J12304 G0 ( 4) G0 ( 4) 
3 J32268 G3 (1) G1+ ( 2.5) 
4 J73325/0153-17 G0 ( 4) G0 ( 4) 
5 J73308/0197-17 G3(1) G1+ ( 2.5) 
6 J77120/033-18 G3 ( 1) G1+ ( 2.5) 
7 J73621/0230-17 G0 (4) G0 (4) 
8 I75399 G2 (2) G1(3) 
9 J83360 G3 (1) G1+ (2.5) 
10 J42382/0244-17 G4 (0) G2 (2) 
11 J94318/0184-18 G3 (1) G1+ (2.5) 
12 J78239 G2 (2) G1(3) 
13 J91230 G2 (2) G1 (3) 
14 J89415 G2 (2) G1(3) 
15 J57667/0290-18 G3 (1) G1+ (2.5) 
16 F84077/0606-18 G3 (1) G1+ (2.5) 
17 J97621 G2 (2) G1(3) 
18 J97076 G2 (2) G1(3) 
19 K03676/0431-18 G3(1) G1+ (2.5) 
20 K10779/0422-18 G2 (2) G1+ (2.5) 
21 K10780/0423-18 G2(2) G1+ (2.5) 
22 K12603 G2 (2) G1(3) 
23 E89125 G2 (2) G1(3) 
24 K18069 G3(1) G1+ (2.5) 
25 I69163 G4 (0) G2 (2) 
26 J45333 G2 (2) G1 (3) 
27 J88827 G3 (1) G1+ (2.5) 
28 K20331/ 0562-18 G2(2) G1 (3) 
29 K18463/0512-18 G3 (1) G1+ (2.5) 
30 J85220/0614-18 G4 (0) G3 (1) 
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Before treatment After treatment 
Grading No of cases Grade 0 Grade1 Grade1+ Grade2 Grade 3 Grade 4 
Grade 0 3 3 - - - - - 
Grade1 - - - - - - - 
Grade1+ - - - - - - - 
Grade2 12 - 10 2 - - - 
Grade 3 12 - 1 11  - - 
Grade 4 3 - - - 2 1 - 
Total 30 3 11 13 2 1  
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Result: 
Based on the Modified Ashworth scale 30 Balavaatham children were selected 
for the trial, out of them 3 children were reported with Grade 0 (Score 4) (No increase in 
muscle tone) but with the features of difficulty in using the limbs, after treatment they 
had Grade 0 (Score 4) but the difficulty in using the limbs was gradually reduced finally 
they were able to walk freely. 
Out of the remaining 27 children, 12 children were reported with Grade 2 (Score 
2) at the onset of the treatment, out of them the clinical conditions of 10 children (83.3%)  
were improved to Grade 1 (Score 3) stage, and the remaining 2 children (16.6%) were 
improved to Grade 1+ (Score 2.5) stage at the end of the treatment, this showed a good 
prognosis. 
Out of 12 children with Grade 3 (Score 1) at the onset of the treatment, single  
(8.3%) child was improved to Grade 1 (Score 3) and the remaining 11children (91.6%) 
were improved to Grade 1+(Score 2.5) level. 
Out of 3 children with Grade 4 (Score 0) at the onset of the treatment, 2 children 
(66.6%) were improved to Grade2 (Score2) level and a single child (33.3%) remains 
static with the same symptoms as Grade 4(Score0). 
At the end of the treatmental course, very good improvement was noted, from the 
trail drug it is proved that, that the drug.  The drug reduced the Spasticity of the affected 
children. 
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STATISTICAL ANALYSIS  
 
All collected data were entered into MS Excel softwares using different columns 
as variables and  row as patients.  SPSS software is used to perform statistical analysis.  
Basic descriptive statistic include frequency distributions and cross- tabulations were 
performed.  The quantity variables were expressed as Mean ± Standerd Deviation and 
qualitative data as percentage. A probability value of >0.0000 was considered as indicate 
the statistical significant paried ―t‖ was performed for determining the significan 
between before and after treatment. 
 
Paired sample Statistic (Spasticity Scale) Score Before treatment and After 
treatment 
Variable Obs Mean ± St   95% of con. I pValue t Value 
Before treatment 30 1.6 ± 1.037 1.212 
11.58>0.0001 
After treatment 30 2.75± 0.598  2.526 
 
The mean± standard deviation of Spasticity scale score at before and after 
treatment were 1.6±0.1.037and 2.75±1.0.598 respectively which is statistically 
significant (t=11.58, p>0.0001).   
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DISCUSSION 
The about Preclinical and clinical evaluation of baala vaatham (paresis) with 
siddha therapeutic management in children, conducted with the trial drug  ―Chitra Mutti 
kudineer‖ (Internal) and Baala Vaatha thylam (External) in reducing the spasticity and 
restricted movement in treating Baala Vaatham. The clinical features of Baala Vatham  
in siddha literature can be correlated to Paresis  in modern science. Paresis is a condition 
typified by a weakness of movements, or partial loss of voluntary movement or  impaired 
movement.  
Baala Vaatham  is a vaatha disease which causes derangements of Vaathakutram 
which causes increasing kabam and pitha kutram.  
Vaathathathu is responsible for the functioning of udal Thathukal uniformly 
derangement of Vaatha kutram leads to  pricking pain over the body, body ache and 
increase in the  Pitha kutram causes swelling and increased body temperature, finally 
Kaba kutram accompanies causing stiffness, restricted of movements.  
As Baala Vaatham  is caused due to the  damage of  nervous system, especially 
the spinal cord, the trial  drugs which possess the property of Anti-vaatha, Anti-
inflammatory, Analgesic, Tonic, Stimulant, Neuroprotective, Nervine tonic,  Nutritive, 
Anti-oxidant property as mentioned in siddha literature were selected,  and the trail drug 
were prepared by the Author in the Gunapadam practical laboratory of  National Institute 
of Siddha, after getting proper authentication of raw drugs from the Medicinal botany 
department at NIS, Chennai 47, under the supervision of the  guide.  National Institute of 
Siddha, Chennai - 47. The trial drug was prepared by the standard operating procedure as 
mentioned in the protocol.  
The Physicochemical analysis was done at the physicochemical lab of The 
Dr.M.G.R. University Chennai respectively. It revealed the presence of physicochemical 
level.  
The Phytochemical analysis was  done at the phytochemical lab of The  
Dr.M.G.R.University Chennai respectively. It revealed the presence of the 
Carbohydrates, Saponins, Flavanoids, Diterpenes, Quinones. 
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 The Biochemical qualitative and quantitative analysis were done at the 
biochemistry lab of NIS Chennai respectively. It revealed the presence of effective 
minerals and the existence of the drug molecules at micro level.  
The safety of the trial drug usage and standardization of the trial drug through 
biochemical analysis were also ensured during the study.  
The Preclinical toxicity studies (acute Toxicity) for the above said trial drug was 
conducted at National Institute of Siddha, after getting the proper acceptance and 
permission from the Institutional Animal Ethical Committee (IAEC). The trial drug was 
proved to be safe for human beings from the observations made from the study.  
The clinical study was conducted with a well-defined protocol and a proper 
proforma after the approval of the Institutional Ethical Committee. After screening 
patients reporting at the OPD of department of Kuzhanthai Maruthuvam, 30 cases were 
selected for induction to the trial. Before enrolment into the trial the informed consent 
was obtained from the parents.  
30 children of both genders were recruited for this study. Among the 30 patients 
15 were treated in OPD children and the remaining 15 were treated in IPD children, visit 
the hospital daily. For In children, who were not in a situation to stay in the hospital for a 
long time, were advised to attend the Out-Patient Department of Kuzhanthai 
Maruthuvam for further follow- up.   
            The treatment was aimed at normalizing the deranged thodams and providing 
relief from symptoms.  
The children was  treated with trial drugs Chitra Mutti kudineer 5 to 15ml  twice 
a day with palm jagery and Baala Vaatha thylam (external) for 45 days . Parents were 
instructed to give medicines regularly, advised to follow pathiyam (avoid tamarind, 
tubers, etc.) and advised to avoid cold exposure .Out-Patients were advised to visit the 
OPD daily for general massage. For Out-Patients the drugs were given for 45days and 
the clinical assessment was done on 0th day, and 45th day.   
After the treatment, parents were advised to bring the children to visit the Out-
Patient ward of Department of Kuzhanthai Maruthuvam for follow-up.  
From this  study, the  affected gender of the disease was found to be high in male 
gender.  Among 30 children 53.3% males and 46.6%females was affected . 
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In this study, 56.6 % of children came under the age group between 2-5 years, 
38.3% of children were under the age of 6-9 years, 10 % of children were between 10-12 
years. 
In this study, based on the socio economic state, 36.6% come under upper middle 
class , 26.6% were lower middle and upper middle level income group, 6.6%  were  from  
lower  level income group and 3.3% were from upper level income group.  
Among 30 children, 86.6% of patients non vegetarian and 13.3% of patients were 
vegetarian. 
Among the 30 children, 76.6% of children from Neithal thinai, 16.6% of children  
from Marutham  and 6.6%  from Kuruinji thinai. 
 In this study Out of 30 children, 40% of the children were treated in Munpani 
kaalam, 20% of them  in Pinpani kaalam, 20% in illavenir kalam, 6.6% children were 
treat in Muthuvenil kalam and the remaining 3.3%  in Kaarkalam.  
In 30 children, 83.3 cases cunder Rasogunam, 10% under Sathuva Gunam, 6.6% 
under Thamogunam.    
Among 30 children, all of them came under  thontha thegi. 
In Vaatham, Viyaanan and Samanan affected in all the 30 children (100%), In 6% 
children Abaanan affected  and in 10% of children  koorman  was affected.  
   In Pitham, Anar pitham was affected in 20% of cases, Ranjagapitham and 
Saathagam  affected in  all the 100%  of cases.  
Among the 30 cases, Avalambagam and Santhigam affected in all the 30 cases.  
In Envagaithervugal, Sparisam was affected in all the 30 cases. The Naadi in 
Baala Vaatham was recorede as 40% with Vathapitham, 10% pithavatham, 4% Kaba 
Vatham, 6% which Kabapitham. 
  Among 30 cases, in 8 cases(26.6%)  was found to be with Vaatha neer, 5 cases 
(17%) with pita neer, and17cases (56.6%) With kaba neer. 
In this study, Saaram, Senneer and Oon were affected in all the 30 cases (100%). 
Kozhuppu was affected in 20 cases (66.6%) 
In Kanmendrium, Kai was affected in 15 cases (50%) and Kaal was affected in 
28 cases (93.3%). 
 120  
During cranial nerve examination 2 children showed abnormality in optic, 
trigeminal, facial and spinal accessory nerves and one child shows abnormality in 
glossopharyngeal nerve and Vestibulo cocclear nerve. 
Among 30 cases 40% of the cases were recorded as para paresis, 33.3% as Hemi 
paresis,13.3% as Mono paresis 10% as Quadri paresis and remaining 3.3% as Triparesis. 
 Among  the 30 children, 5 ( 16.6% )children had a normal bulk of the ,muscle 
before the onset of treatment but they had difficulty  in using  the limbs and  the 
remaining 25 (83.3%) were  affected in the muscle bulk.  After the course of treatment 
the 83.3%  affected children’s muscle bulk was gradually improved. 7 cases had no 
improvement in their muscle bulk. 
 All the children were found have hyper tonia and after treatement the spasticity 
was reduced in 93% (28) of the children, remaing 7% (2) children spasticity was static.  
30  hypertonic children were selected for the study, among them  28 children’s 
muscle tone  was  improved to the normal tonic stage during the treatment period and 
remaining 7 children had no improvement in their muscle tone. 
 In the superficial reflex mostly 90% children had a positive reflex and 10% in 
negative. after that the child reflex improve about 93.3% and remains 6.6% in a same 
level. 
In the superficial reflex  
 In the right biceps muscle was affected in a 43.3% children and it was reduced 
6% to after the treatment . 
In left biceps muscle was affected in a 36.6% children and it was reduced 26.6% 
to after the treatment.  
In the right triceps muscle was affected in a 43.3% children and it was reduced 
4% to after the treatment 
In the Left triceps muscle was affected in a 36.6% children and it was reduced 
26.6% to after the treatment 
In the Right Supinator muscle was affected in a 43.3% children and it was 
reduced 20% to after the treatment 
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In the Left Supinator muscle was affected in a 36.6% children and it was reduced 
20% to after the treatment 
In the Right knee jerk was affected in a 66.6% children and it was reduced 16.6% 
to after the treatment 
In the Left knee jerk was affected in a 63.3% children and it was reduced 30% to 
after the treatment 
In the Right Anke jerk was affected in a 76.6% children and it was reduced 7% to 
after the treatment 
In the Left Anke jerk was affected in a 70% children and it was reduced 40% to 
after the treatment 
The spasticity assessment was done in all the 30 children  based on Ashworth and 
Modified Ashworth scale.  
Based on the Modified Asworth scale – Totally 30 children ware treated for 
Balavaatham out of them 3 children ware reported with Grade 0 (No increase in muscle 
tone) but with features of difficulty in using the limbs, after treatment they had Grade 0 
but the difficulty using the limbs was improved and they ware able to walk feely. 
Out of the remaining 27 children 12 children reported with Grade 2 at the onset 
of the treatment out of them 10 (83.3%) children had which exhibits Grade 1, and 2 
(16.6%) children had Grade 1+ at the end of the treatment.  Which shows  a good 
improvement. 
Out of 12 children with Grade 3 at the onset of the treatment 1 (8.3%) child 
improved to Grade 1 and 11(91.6%) children had improvement to Grade 1+. 
Out of 3 children with Grade4 before treatment 2 (66.6%) children improved to 
Grade2 and 1(33.3%) child remains static at the same condition as Grade 4. 
As there is a very good improvement in the treated children. 
The short term toxicity study was conducted for the trial drug CHIRTA MUTTI 
KUDINEER in National Institute of Siddha and it showed no abnormal results. Hence 
the safety of the trial drug was also proved.  
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SUMMARY 
    
The disease Baala Vaatham was taken for the clinical study with Chitramutti 
Kudineer Chooranam as internal medicine and Baala Vatha thylam as external 
application. For the clinical study, 30 children were selected based on the approved 
protocol.  This study has been approved by IEC of NIS [Date of IEC Approval & its 
number: NIS/IEC/2016/11-22/14.10.2016]. Animal studies were carried out after 
obtaining approval from the Institutional Animal Ethical Committee (IAEC) Approval & 
its number NIS /IAEC – IV/06/05012017 and the trial was registered in Clinical Trial 
Registry of India CTRI/2018/04/013296) Hence the study is safely executed on children 
and there was no adverse drug reactions noted during the study period.   
 
The toxicological evaluations were conducted as per WHO guidelines for safety 
evaluation of Chitramutti Kudineer Chooranam.  In acute toxicity study, no signs of  
toxicity and mortality were observed throughout the study. In organs of Control group, 
no abnormality was detected.  In the necropsy normal  structure present in test group of 
animals. 
 
       30 children, were treated with trial medicine in OPD, IPD of Department of 
Kuzhanthai Maruthuvam, Ayothidoss Pandithar Hospital of National Institute of Siddha, 
Chennai-47. The detailed study on Chitra mutti Kudineer Chooranam with reference to 
its aetiology, pathogenesis, clinical features, diagnosis and treatment with trial drugs 
were done. The children were diagnosed and included on the basis of MODIFIED 
ASHWORTH scale (Spasticity Assessment scale) and the results were observed by 
Modified Ashworth scale  before and after treatment.   
 
Based on the Modified Ashworth scale – Totally 30 children ware treated for 
Balavaatham out of them 3 children were reported with Grade 0 (No increase in muscle 
tone) but with features of difficulty in using the limbs, after treatment they had Grade 0 
but the difficulty using the limbs was improved and they were able to walk feely. 
 
Out of the remaining 27 children 12 children reported with Grade 2 at the onset 
of the treatment out of them 10 (83.3%) children had which exhibits Grade 1, and 2 
(16.6%) children had Grade 1+ at the end of the treatment.  Which  good improvement. 
 
 123  
Out of 12 children with Grade 3 at the onset of the treatment 1 (8.3%) child 
improved to Grade 1 and 11(91.6%) children had improvement to Grade 1+. 
 
As there is a very good improvement after treatment as noted above it can be 
concluded that the drug has reduced the spasticity of  the affected children. 
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CONCLUSION 
 
The acute Safety study conducted on the trial drug shows that the trial drug 
Chitra mutti kudineer Chooranam (Internal) safe for human usage.    
The Physiochemical analysiscarried out proves the percentage of Loss on drying, 
Total Ash value, Acid insoluble ash, Water soluble ash, Water soluble extraction, 
Alcohol soluble actions. 
The  Phytochemical analysis shows  the presence  of Carbohydrates, Flavonoids, 
Saponin, Diterpins, Quinones.   
The biochemical analysis shows the presence of Potassium, and Iron, Chloride, 
Phosphate, Alkaloids, Tannic acids .  
This study proved that  formulation of (medicine /drug)has given good results in 
many children through clinical trials and it may be better solution for reducing the 
muscle dryness, spasticity, increasing the blood circulation, increasing the nervine 
strength, muscle bulk, tone, power, and reflex thereby reducing the inability or difficulty 
of movements in the affected limb. This has created confident in paresis children to 
improve their quality of life and to perform their day to day activities. It also reduces the 
risk of their parents and freed them from their physical and mental burden.   
No adverse effects were noted during the course of treatment.   
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI- 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL EVALUATION OF BAALAVAATHAM 
(PARESIS) WITH SIDDHA THERAPEUTIC MANAGEMENT IN CHILDREN 
Form I- SCREENING 
 
1. S.I. No:  2. OP/IP No:  3. Name: 
4.   Age     :  5. Gender    :  6. Date of Enrolment 
7. Informant:  8 . Reliability: 
 
INCLUSION CRETERIA: 
S. No Inclusion Yes No 
1. Children of age group under 2-12 years   
2. Mono/Para/Hemi/Tri/Double/Tetra/Quadri paresis   
3. Weakness of one or more limb   
4.  Loss of power and tone in muscles of the affected limb   
5. Difficulty/  Inability in using the affected limb against gravity and 
resistance 
  
6. Difficulty in using the affected limb   
 
EXCLUSION CRETERIA: 
S.No Exclusion Yes No 
1. H/o Epilepsy   
2. Severe Aggressiveness  with ADHD   
3. Autism   
4. H/o cerebral palsy   
5. Congenital Heart Disease   
6.  Any other serious illness   
 
ADMITTED TO TRIAL:    Yes/No    Signature of the Investigator 
IF YES, SERIAL NO      :  
            Signature of the Guide  
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI- 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL EVALUATION OF BAALAVAATHAM 
(PARESIS) WITH SIDDHA THERAPEUTIC MANAGEMENT IN CHILDREN 
 
FORM II -CONSENT  
CERTIFICATED BY INVESTIGATOR 
 I  Certify that I have enclosed all the details about the study in the terms readily 
understood by the parent/guardian. 
 
Signature         ________________________ 
Date  ________________________ 
Name  ________________________ 
 
CONSENT BY PARENT 
 I have been informed to my satisfaction, by the attending physician, the purpose 
of the clinical evaluation, and the nature of disease and its treatment and follow-up  
including external therapy  to be performed to monitor and safeguard my son/daughter’s 
body functions. 
 I am aware of my rights to my son/daughter out of the clinical assessment at any 
time during the course of the clinical assessment without giving to give the reasons for 
doing so. 
I, exercising my free of choice, here by give my consent to include my 
son/daughter as a subject in the  ―pre clinical and Evaluation of Baalavatham (Paresis) 
with siddha therapeutic management in children‖. I also give my consent to take 
photography when and where it is considered as essential. 
 
Date:                  Signature                    ____________________ 
       Name                     ____________________ 
      Signature of the witness    ___________________ 
      Name          ____________________ 
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Njrpa rpj;j kUj;Jt epWtdk; 
mNahjpjhr gz;bjh; kUj;Jtkdi nrd;di 600 047. 
Foe;ij kUj;Jtj;Jiw 
 
ghythj Nehapd; kjPg;gPl;bidf; fz;lwpAk; Ma;tpw;fhd xg;Gjy; gbtk;  
 
Ma;thsuhy; rhd;wspf;fg;gl;lJ. 
 
ehd; ,e;j kUj;Jt Ma;T Fwpj;J midj;J tpguq;fisAk; Foe;ijapd; 
ngw;NwhUf;F GupAk; tifapy; vLj;Jiwj;Js;Nsd; vd cWjp mspf;fpNwd;. 
 
Njjp:     ifnahg;gk;: 
,lk;:     ngah;: 
 
Foe;ijapd; ngw;NwhH xg;Gjy; gbtk; 
 
vd;dplk; ,e;j kjpg;gPl;bidf; fz;lwpAk; Ma;tpd; fhuzj;ijAk; kUe;jpd; 
jd;ik kw;Wk; kUj;Jt topKiw gw;wpAk; GwkUj;Jt rpfpr;irapd; mtrpak; 
gw;wpAk; jpUg;jp mspf;Fk; tifapy; Ma;TkUj;Jtuhy; tpsf;fp;f; $wg;gl;Ls;sJ.  
ehd; ,e;j kjPg;gPl;bidf; fz;lwpAk;  kUj;Jt Ma;tpd; NghJ fhuzk; vJTk; 
$whky; vg;NghJ Ntz;LkhdhYk; vd; Foe;ijia tpLtpj;Jf; nfhs;Sk; 
chpikia njhpe;jpUf;fpNwd;. 
 ehd; vd;Dila Rje;jpukhf Njh;T nra;Ak; chpikiaf; nfhz;L ghythj 
Nehapd; kjpg;gPl;bidf; fz;lwpAk; kUj;Jt Ma;T kw;Wk; ,jw;fhd kUe;J 
“rpw;whKl;b FbePu” ; (cs;kUe;J) “ghythjj; ijyk”; (ntspkUe;J) gupfhpg;Gj; 
jpwidf; fz;lwpAk; Ma;tpw;F vdJ Foe;ijia cl;gLj;j xg;Gjy; mspf;fpNwd;. 
NkYk; ,e;j Ma;tpd; NghJ Njitg;gLk; ,lj;jpy; vdJ kfd;(m) kfis 
Gifg;glk; vLg;gjw;F ehd; xg;Gjy; mspf;fpNwd;. 
 
 
Njjp:     ngw;Nwhu; ngah;:    
  
,lk;:     ifnahg;gk;: 
     rhl;rpf;fhuh; ngau;:    
  
     ifnahg;gk;:  
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI- 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL EVALUATION OF BAALAVAATHAM 
(PARESIS) WITH SIDDHA THERAPEUTIC MANAGEMENT IN CHILDREN 
 
FORM III - PATIENT INFORMATION SHEET 
 
Name of the principal Investigator : ________________________ 
Name of the Institute    : National Institute of siddha, 
      Tambaram Sanatorium, 
      Chennai – 47. 
 
INFORMATION SHEET FOR PATIENTS PARTICIPATING IN THE OPEN 
CLINICAL TRIAL. 
  
I, _______________________________________ studying as PG scholar at 
National Institute of siddha, Tambaram Sanatorium is doing a clinical trial on Baala 
Vaatham.“BAALA VAATHAM “(Paresis) -  is a condition of muscular weakness 
caused by nerve damage.  It is characterised by weakness of voluntary movement of one 
or more limbs.   In the siddha literature Madhalai noi thoguthi – III it has been illustrated 
that Baalavaatham is characterised by Inability/ Difficulty to use both the limbs, loss of 
power in the limb,  weakness of nerves , increased kabba hummer in the body, chilness 
of the body and spastisity of the affected muscles.  I would conduct a children trial on 
Baala vaatham with the medicine chitramutti kudineer mentioned in the siddha text 
Tharala mani Balavagadam and Balavatha thylam (external) mentioned in the text 
Madhalai noi thoguthi III .   Prevalence of paresis in the united states nearly 1 in 50 
people living with paresis – approximately 5.4 million people.  
 
Approximately 1.7 percent of the U.S. population, or 5,357,970 people reported 
they were living with some form of paresis.  In this regard, i am in a need to ask you are 
few questions.  I will maintain confidentiality of your comments and data obtained. 
There will be no risk of disclosing your identity and no physical, psychological or 
professional risk is involved by taking part in this study.  Taking part in this study is 
voluntary.  No compensation will be paid to you for taking part in this study.   
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You can choose not to take part.   However, taking part in the study may be of 
benefit to the community, as it may help us to understand the problem of defaulters and 
potential solutions.   In the event of any adverse effect the child will be given full care in 
NIS.  If your agree your child to be a participant in this study, he/she will be included in 
the study primarily by signing the consent for and then you will be given the  Chitr Mutti 
Kudineer (Internal Medicine) 5-15ml  twice a day and Baala vatha thylam (External 
therapy) for a period of 45 days.  The information I am colleting in this study will remain 
between you and the principal investigator (Myself). This study has been approved by 
the IEC of NIS/IEC/2016/11-22/14.10.2016. The questionnaire will take approximately 1  
hour of your time.  If you wish to find out more about this study before taking part, you 
can ask me all the questions. You can also contact the member- secretary of Ethics 
committee, National Institute of Siddha, Chennai 600 047.  Tel no : 91-44-22380789, for 
rights and participation in the study. 
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Njrpa rpj;j kUj;Jt epWtdk; 
mNahjpjhr gz;bjh; kUj;Jtkdi nrd;di 600 047. 
Foe;ij kUj;Jtj;Jiw 
ghythj Nehapd; kjPg;gPl;bidf; fz;lwpAk; Ma;tpw;fhd jfty;; gbtk; 
 
ghythj Neha;f;fhd kjPg;gPl;bidf; fz;lwpAk; Ma;T kw;Wk; rpj;j kUe;J 
“rpw;whKl;b FbePu;” (cs;kUe;J) kw;Wk; “ghythj ijyk”; (ntspkUe;J) 
ghpfhpg;Gj;jpwidf; fz;lwpAk; kUj;Jt Ma;tpw;fhd jfty;; gbtk;. 
 
Kjd;ik Muha;r;rpahsh; ngah;  :  kU. f. upjk;guhNjtp 
epWtdj;jpd; ngau;      :  Njrpa rpj;j kUj;Jt epWtdk; 
       jhk;guk; rhdl;Nlhhpak; nrd;id 47. 
 
 Njrpa rpj;j kUj;Jt epWtdj;jpy; gl;l Nkw;gbg;G gapd;W tUk; ehd;, 
“ghy thjk;” ; vd;Dk; Nehapd; kUj;Jt Muha;;r;rpapy; <Lgl;Ls;Nsd;. ,e;NehahdJ 
euk;Gfis ghjpj;J, if fhy;fis mirf;f Kbahky;; jsh;Tur; nra;Ak; 
,ay;GilaJ, Mw;wy; Fiwe;J fhzg;gLk;> if fhy;fs; tpsq;fplhJ, 
euk;ngy;yhk; jsh;e;J epw;;f;Fk; tpir jsWk; rPjk; Njhd;Wk; Njfj;jpy; Fsph;r;rp 
cz;lhFk; Njfk; tpiwj;J fhzg;gLk;, vd;Dk; ,ay;Gila Neha; vd;Wk; 
mjw;fhd(ntspkUe;J) “ghythjj; ijyk;” ; kjiy Neha; njhFjp-2 vd;Dk; rpj;j 
kUj;Jt Ehypy; Fwpg;gplg; gl;Ls;sJ. (cs;kUe;J) rpw;whKl;b FbePh; ,jid 
“juskzpgy thflk”; vd;Dk; EhypYk; nfhLf;fg;gl;Ls;sJ.   
   
,e;j Muha;r;rp rk;ke;jkhf rpy Nfs;tpfis jq;fsplk; Nfl;fTk; 
gupNrhjidf;F jq;fsJ Foe;ijia cl;gL;j;jTk; cs;Nsd;. ,J rk;ke;jkhd 
jq;fsJ Foe;ijapd; midj;J tpguq;fisAk; ufrpakhf itf;fg;gLk; vd 
cWjp mspf;fpNwd;. ,jpy; gazg;gb vJTk; nfhL;f;fg;gl khl;lhJ. ,e;j 
Muha;;r;rpapd; NghJ jq;fsJ Foe;ijapd; clYf;F NtWghjpg;G Vw;gLk;gl;rj;jpy; 
Njrpa rpj;j kUj;Jtkidapy; jf;f rpfpr;ir mspf;fgLk;. 
 
,e;j Muha;r;rpf;F jq;fs; tpUg;gj;jpd; Ngupy; Foe;ijia cl;gLj;Jk; 
gl;rj;jpy; (cs;kUe;jhf) ‘rp;w;whKl;b FbePh; 45ehl;fs; ,UNtis gid 
nty;yj;JlDk; (ntspkUe;jhf) ghythj ijyk; vL;f;f Ntz;Lk;.  
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,;e;j Muha;;r;rpapy; Nehapduhf Nrh;e;j gpwF jq;fSf;F tpUg;gk; ,y;iy 
vdpy; vg;NghJ Ntz;LkhdhYk; jq;fsJ Foe;ijia ,e;j Ma;tpypUe;J 
tpyf;fpf;nfhs;syhk;. 
 
,e;j Muha;r;rpf;F Njrpa rpj;j kUj;Jt ePjpnewp FOthy; xg;Gjy; 
ngwg;gl;Ls;sJ. rhd;wpjy; vz; IEC of NIS/IEC/2016/11-22/14.10.2016. ,e;j 
Muha;;r;rp rk;ke;jkhf kw;w tpguq;fSf;Fk; Nehapd; jd;ik gw;wpAk; mwptjw;f;Fk; 
Kjd;ik Muha;r;rpahsuhd kU. f. upjk;guhNjtp (gl;l Nkw;gbg;ghsh; Foe;ij 
kUj;Jt gphpT) ifNgrp vz;.7708738987 vg;NghJk; njhlu;Gnfhs;syhk;. NkYk; 
,;e;j Muha;;r;rp;f;F rk;ke;jkhd chpik kw;Wk; gq;fspg;G gw;wp njhpe;Jnfhs;s 
IEC Tel No : 91-44-22380789 njhlh;G nfhs;sTk;.   
 
,e;j kUj;Jt Muha;r;rpapy; gad;gLk; kUe;Jfs; rpwg;ghf ghythj 
Neha;f;fhf mq;fPfupf;fg;gl;l rpj;j kUj;Jt Ehypy; $wg;gl;ls;sJ. Vw;fdNt 
cgNahfj;jpy; cs;sJ ve;j tpj gf;ftpisTfisAk; Vw;gLj;jtpy;iy. NkYk; 
Muha;r;rpf;F cl;gLj;Jk;NghJ czTKiwapy; gj;;jpak; fhf;FkhW 
mwpTWj;jg;gLfpwJ. 
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POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
 
PRECLINICAL AND CLINICAL EVALUATION OF BAALAVAATHAM 
(PARESIS) WITH SIDDHA THERAPEUTIC MANAGEMENT IN CHILDREN 
 
FORM ASSENT  - IV FORM 
 
I ______________________________ understand that my parents (mom and 
dad) / guardian have / has given permission (said its okay) for me to take part in the 
project above done by ____________________________ 
 
 I am taking part because I want to.  I have been told that I can stop at any time I 
want to and nothing will happen to me if I want to stop. 
 
 
 
 
 
           
           _____________________ 
 
         Signature 
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Njrpa rpj;j kUj;Jt epWtdk; 
mNahjpjhr gz;bjh; kUj;Jtkdi nrd;di 600 047. 
Foe;ij kUj;Jtj;Jiw 
ghythj Nehapd; kjPg;gPl;bidf; fz;lwpAk; Ma;T 
 
 xg;Gjy; gbtk; Foe;ijf;fhdJ 
________________ Mfpa ehd; Njrpa rpj;j kUj;Jt  epWtdj;jpy; gl;l 
Nkw;gbg;G Foe;ij kUj;Jtj;Jiwapy; gapYk; kU. f. hpjk;guhNjtp mth;fshy; 
elj;jg;gLk; ghythj Neha;f;fhd rpw;whKl;b FbePh; (cs;kUe;J) kw;Wk; ghythj 
ijyk; (ntspkUe;J) ghpfhpg;Gj; jpwid fz;lwpAk; kUj;Jt Ma;tpy; 
gq;Nfw;gjw;F vdJ ngw;Nwhh; / fhg;ghsh; jpU/ jpUkjp  
___________________________  rk;kjk; njhptpj;jpUg;gij ed;F mwpNtd;. 
 
vdf;F ,e;j Muha;r;rp gw;wp GhpAk; tifapy; vLj;Jiuf;fg;gl;Ls;sJ.  
,t;thuha;r;rpapy; ,Ue;J vg;NghJ Ntz;LkhdhYk; tpyf vdf;f cupik 
,Uf;fpd;wJ vd;gij gw;wpAk; ed;F njhpe;j nfhz;L ,e;j Muha;r;rpapy; gq;Nfw; 
rk;kjpf;fpNwd;. 
 
Njjp:       Foe;ijapd; ngah;  : 
,lk;:       ifnahg;gk;        : 
       ngw;Nwhh; ifnahg;gk; : 
       ifnahg;gk;        : 
       rhl;rpfhuh; ifnahg;gk;: 
       ifnahg;gk;        : 
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(PARESIS) WITH SIDDHA THERAPEUTIC MANAGEMENT IN CHILDREN 
 
FORM V - CASE RECORD FORM 
       1. S.I. No      :   2. OP/IP No:  3. Name: 
4. Age           :   5. Gender    :  6. Date of Enrolment: 
7. Informant:              8 . Reliability: 
 
COMPLAINTS AND DURATION: 
 
 
 
H/O PRESENT ILLNESS: 
 
 
H/O PASTILLNESS: 
 
 
TREATMENT HISTORY: 
 
H/O CONTACT: 
 
ANTENATAL: 
 H/o Fever with rash    : 
 H/o Painful lymph adenopathy  : 
 H/o Threatened abortion   : 
H/o Severe anaemia    :     
H/o Pre eclampsia                      :  
Maternal DM/HT                  : 
H/o Decreased foetal movements        : 
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NATAL: 
 H/o prolonged labour                : 
 H/o Pre term delivery    :  
 Nature of delivery    : (Home/Hospital) 
 Forceps/C-section                : 
H/o Birth injury               : 
 H/o Breech presentation              : 
 
NEONATAL HISTORY: 
 Birth weight of the baby    : 
 H/o Fever/ Rash     : 
 H/o Petechial haemorrhages    : 
H/o Neonatal Jaundice    : 
H/o Cyanosis      : 
H/o Breathlessness at birth    : 
Neonatal convulsion     : 
H/o Poor feeding     :      
H/o Resuscitation done or not              : 
 H/o Lethargy      : 
 H/o Umbilical catheterisation    : 
 
 
DEVELOPMENTAL MILE STONE: 
 
Cry at birth        
Smile         
Head control        
Laughed out loud        
Sit with support        
Rolled over          
Transfer         
Sit without support cowl       
First ward & walk with support    
Stand          
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Walk without support        
Put wards together                   
Ride tricycle         
Hops on one foot          
Known (R)/(L)   
 
DIETARY OR NURTITIONAL HISTORY: 
 
 IMMUNIZTION HISTORY: 
 
PERSONAL HISTORY: 
FAMILY HOSTORY: 
 H/o Convulsion   : 
 H/o Neurological disorder       : 
 H/o Metabolic disorder  :    
 
FAMILY HISTORY: 
 Whether this problem runs in family?          1.Yes  2.No 
 If yes, mention the relationship of affected person(s) 
 
DIETARY  HISTORY: 
 Appetite: poor/moderate/good 
 Type of diet- vegetarian / Non vegetarian  
 
SOCIAL AND ENNVIRONMENTAL HISTORY: 
 
GENERAL EXAMINATION: 
1. General appearance    : Healthy/unwell/ill 
2. consciousness and mental state  : 
                  Normal/Delirium/Lethargy/Obtundation/Stupor/Coma  
3. Nutritional status    : 
4. Growth problems    : 
  
 140  
a) General growth retardation   : 
b) Localised growth retardation  : 
c) Tall/Short     : 
d) Obese/Thin     : 
5. Posture                               : 
6. Vital signs     : 
a)  Heart rate      : 
b)  Pulse      : 
c)  Respiratory rate    : 
d)  Blood pressure    : 
e)  Temperature    : 
7. Anthropometry    : 
a) Weight     : 
b) Height/ Length     : 
c) Head circumference   :  
d) Midarm circumference   :  Rt   Lt  
e) chest measurement    : 
f) Skin fold thickness    : 
g) Upper segment to lower segment ratio       : 
h) Arm span      : 
 
HEAD TO TOE EXAMINATION: 
 Head     : 
 Eyes     : 
 Face     : 
 Neck     : 
 Limb  
  Upper limbs :  length  Rt             Lt 
  Lower limbs    : length  Rt        Lt 
    Intercondylar distance& 
    Inter malleolar distance 
 Skin   : 
 Odour of the body : 
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EXAMINATION OF CENTRAL NERVOUS SYSTEM: 
 
HIGHER FUNCTION TEST: 
1. Cognitive functions     : 
a) Orientation         : 
b) Attention and concentration  : 
c) Memory        : 
2. Appearance    : 
3. Mood    : 
4. Speech    : 
5. Handedness    : 
 
CRANIAL NERVE EXAMINATIONS: 
                   
 
S. 
NO. 
 
CRANIAL NERVE 
NORMAL AFFECTED 
REMARKS 
 
AFTER 
TREAT
MENT 
 
RIGHT/
LEFT 
 
RIGHT LEFT RIGHT LEFT 
1. Olfactory       
2. Optic        
3. Oculomotor        
4. Trochelar        
5. 
Trigeminal  
    Sensory 
     Motor 
      
6. Abducent        
7. 
Facial  
     Sensory 
     Motor 
      
8. vestibulo cochlear        
9. 
Glassopharyngel 
     Motor 
     Sensory 
      
10. 
Vagus  
     Sensory 
     Motor 
      
11. Spinal accessory       
12. Hypoglossal        
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EXAMINATION MOTOR SYSTEM: 
S.NO 
MOTOR 
SYSTEM 
NORMAL 
RIGHT     
LEFT 
AFFECTED 
RIGHT      
LEFT 
REMARKS AFTER 
TREATMENT 
RIGHT/LEFT 
1. 
Nutrition 
   Upper limb 
   Lower limb 
      
2. 
Tone 
    Upper limb 
    Lower limb 
      
3. 
Power 
 Upper limb 
     Hand 
     Fore arm 
     Arm 
     Fingers 
      
 Lower limb 
    Thigh 
     Leg 
     Foot 
     Toe 
      
4. 
Reflex 
      Superficial 
      Corneal 
      
      
Conjunctival      
      
Abdominal 
       Plantar 
       Cremastic 
      
   Deep 
        Jaw jerk 
        Biceps 
        Triceps 
        Supinator 
        Knee jerk 
        Ankle jerk   
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5. 
Clones 
        Patellar 
        Ankle 
      
6. 
Co-ordination 
   Finger nose 
   Heel knee 
   Finger  Finger      
   nose 
      
7. 
Involuntary 
movements 
      
8. Gait 
      
 
 
SENSORY EXAMINATION: 
S.NO SENSATIONS NORMAL AFFECTED REMARKS 
AFTER 
TREATMENT 
1. 
Superficial  
     Touch 
     Pain 
     Temperature 
    
2. 
Deep 
     Position     
     Joint 
     Vibration 
    
3. 
Cortical 
    Tactile                           
     Localization       
     discrimination 
     Steriognosis 
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CEREBELLAR SIGN: 
AUTONOMIC NERVOUS SYSTEM : 
Bladder movements    : 
Bowel movements                : 
Sweating                             : 
EXAMINATION OF SPINE AND CRANIUM: 
Spine      : 
Cranium     : 
SIGNS OF MENINGEAL  IRRITATION: 
 
EXAMINATION FOR INCREASED ICT: 
 
SOFT NEROLOGICAL SIGNS AND SYMPTOMS: 
 
S. 
NO 
SIGN POSITIVE NEGATIVE REMARKS AFTER 
TREATMENT 
1.  Romberg sign                 
2.  Nystagmus                       
3.  Unsteadiness                   
4.  Intentional tremors         
5.  Pendular jerk                   
6.  Slurring of speech            
7.  Ataxia                            
8.  Meningeal signs if 
any   
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EXAMINATION OF PERIPHERAL NERVOUS SYSTEM: 
 
CLINICAL ASSESSMENT OF THE LEVEL OF THE LESION: 
 
EXAMINATION OF OTHER SYSTEM: 
CVS: 
RS: 
GIT: 
SIDDHA SYSTEM OF EXAMINATION  
KUZHANTHAI PARUVANGAL: REMARKS 
 N A 
1. Kaapu    
2. Thaal    
3. Sangeerai    
4.  Sappani    
5 . Mutham    
6.  Vaaranai    
7.  Ambuli    
8  .Sitril/ Kazhangu    
9. Siruparai/Ammanai    
10. Sirutheer/Osal    
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1. THEGI (TYPE OF BODY CONSTITUION) 
 1. Vaatha udal                                                     2. Pithaudal 
 3. Kaba udal         4. Thonthaual 
 
2. NILAM  (LAND WHERETHE PATIENT LIVED MOST) 
 1. Kurinji      2. Mullai 
 3. Marutham      4. Neithal 
 5. Paalai 
 
3. KAALAM 
 1. Kaarkalam                  2. Koothirkalam 
 3. Munpani kalam      4. Pinpani kaalam 
 5. Illavenirkalam      6. Muthu venil kalam 
4. GUNAM 
 1. sathuvam        2. Thamo gunam  
3.Rasogunam 
5.  PORI/PULANGAL 
 
Sl. 
no 
 
Pori/pulangal 
Right Left Right/Left 
 
Normal 
 
Affected 
 
Normal 
 
Affected 
After 
treatment 
1. Mei/unarvu      
2. Vaai/suvai      
3. kan/parvai      
4. Mooku/natram      
5. sevi olli      
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6. KANMENDHIRIUM 
S. no kanmendhirium 
Right Left 
Right/Left 
After 
treatment 
Normal Affected Normal Affected  
1.  Kai/dhanam      
2.  Kaal/ghamanam      
3.  Vaai/vaaku      
4.  Eruvai/visarkam      
5.  Karuvai/anantham      
 
 UYIRTHAATHUKKAL: 
VAATHAM 
S. No Vaatham Normal Affected Remarks After treatment 
1.  Paranan     
2.  Abananan     
3.  Viyanan     
4.  Uthanan     
5.  Samanan     
6.  Naga      
7.  Koorman     
8.  Kirukaran     
9.  Devathathan     
10.  Dhananjeyan     
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PITHAM: 
S. no Pitham Normal Affected Remarks After treatment 
1. Analagam     
2. Ranjagam     
3. Saathagam     
4. Pirasakam     
5. Alosagam     
 
KABAM: 
S. no Kabam Normal Affected Remarks After treatment 
1. Avalambagam     
2. Kilethagam     
3. Pothagam     
4. Tharpagam     
5. Santhigam     
 
8. UDAL THATHUKKAL: 
S. No Udal thathu Normal Affected Remarks After treatment 
1.  Saaram     
2.  Senneer     
3.  Oon     
4.  Kozhuppu     
5.  Enbu     
6.  Moolai     
7.  Sukilam/suronitham     
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9. DHASA NADIKAL: 
S.No. Naadi Normal Affected Remarks After treatment 
1. Edakalai     
2. Pingalai     
3. Suzhumunai     
4. Sikuvai     
5. Purudan     
6. Kanthaari     
7. Atthi     
8. Alampudai     
9. Sangeni     
10. Kugu     
 
10. ENVAGAI THERVUGAL: 
S. no Envagai thervugal Remarks After treatment 
1.  
Naa      
     Niram 
    Thanmai 
    Suvai 
  
2.  Niram   
3.  
Mozhi     
    Sama oli 
    Uratha oli 
    Thaazhntha oli 
  
4.  
Vizhi     
     Niram 
    Thanmai 
     Paarvai 
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5. 
Malam  
     Niram 
    Nurai 
    Elagal 
    Eugal 
 
  
6. 
Moothiram 
    Neerkuri 
    Niram  
    Manam 
    Kalappu 
   Nurai 
   Enjal 
  Murai 
  
7. Sparisam   
8. Naadi   
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(PARESIS) WITH SIDDHA THERAPEUTIC MANAGEMENT IN CHILDREN 
 
FORM VI - DRUG COMPLAINCE 
 
       1. S.I. No      :  2. OP/IP No:  3. Name: 
4. Age           :  5. Gender:  6. Date of Enrolment: 
7. Informant:  8 . Reliability: 
Internal Medicine: 
Name of the Drug  : Chitra Mutti Kudineer Chooranam 
Form of the Drug  : Kudineer   
Administration  :Per oral 
Dose and Duration  : 5- 15ml -45days 
No of drug packets given : 
No of drug packets returned : 
External Medicine: 
Name of the method   : Baala Vaatham 
Administration : Thokkanam 
Duration  : 45 days 
Date:       Signature of the principal 
Investigator 
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Day Date  Morning  Evening  Day Date  Morning  Evening  
1.    25    
2.    26.    
3.    27.    
4.    28.    
5.    29.    
6.    30.    
7.    31.    
8.    32.    
9.    33.    
10.    34.    
11.    35.    
12.    36.    
13.    37.    
14.    38.    
15.    39.    
16.    40.    
17.    41.    
18.    42.    
19.    43.    
20.    44.    
21.    45.    
22.        
23.        
24.        
 
Date & Station: 
Signature of the investigator: 
 
Signature of the lecturer:                          Signature of the HOD
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI- 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRE CLINICAL AND CLINICAL ASSESSMENT AND EVALUATION OF 
BAALAVAATHAM (PARESIS) WITH SIDDHA THERAPEUTIC 
MANAGEMENT IN CHILDREN 
 
FORM VII - WITHDRAWAL 
 
       1. S.I. No      :   2. OP/IP No:  3. Name: 
4. Age           :   5. Gender    :  6. Date of Enrolment: 
7. Informant:              8 . Reliability: 
  
Date of trial commencement   : 
Date of withdrawal    : 
Reason(s) for withdrawal   : 
Long absence at reporting   : Yes/ No 
Irregular treatment    : Yes/ No 
Shift of locality    : Yes /No 
Complication adverse reaction if any  : Yes / No 
Exacerbation of symptoms   : Yes /No 
Patient not willing to continue  : Yes / No 
 
Date:       Signature of principal investigator 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI- 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRE CLINICAL AND CLINICAL ASSESSMENT AND EVALUATION OF 
BAALAVAATHAM (PARESIS) WITH SIDDHA THERAPEUTIC 
MANAGEMENT IN CHILDREN 
 
FORM VIII -ADVERSE REACTION 
 
       1. S.I. No      :   2. OP/IP No:  3. Name: 
4. Age           :   5. Gender    :  6. Date of Enrolment: 
7. Informant:              8 . Reliability: 
 
Name     : 
Age     : 
Gender    : 
OPD/IPD No    : 
Registration No   : 
Date of trial commencement  : 
Date of withdrawal from trial  : 
Description of adverse reaction : 
 
 
Date:       signature of principal investigator 
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AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI- 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRE CLINICAL AND CLINICAL ASSESSMENT AND EVALUATION OF  
BAALAVAATHAM (PARESIS) WITH SIDDHA THERAPEUTIC 
MANAGEMENT IN CHILDREN 
 
FORM IX - PHARMACOVIGILANCE 
 
       1. S.I. No      :  2. OP/IP No:   3. Name: 
4. Age           :  5. Gender    :   6. Date of Enrolment: 
7. Informant:  8 . Reliability: 
1. patient/consumer identification (please complete or tick boxes below as 
appropriate) 
NATIONAL PHARMACOVIGILANCE PROGRAMME FOR SIDDHA DRUGS 
Reporting Form for Suspected Adverse Reactions to Siddha 
 
Please note: i. All consumers/ patients and reporters information will remain 
confidential. 
  ii. It is requested to report all suspected reactions to the concerned, even if 
it does not have complete data, as soon as possible. 
Peripheral Centre code:      State: 
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Name 
 
Father name 
 
Patient /Record No. 
 
 
 
Ethnicity 
 
Occupation 
 
Address 
Village / Town 
Post / via 
District / State 
 
 
 
 
 
Date of Birth/ Age: 
 
 
 
Sex        :   M/ F 
Weight  : 
Degam  : 
 
1.Description of the suspected Adverse Reactions (Please complete boxes below) 
Date and time of  
initial observation 
       
 
 Season: 
Description of 
Reaction 
 
 
Geographical area: 
 
1. List of all medicines / Formulations including drugs of other system used by the 
patient during the reporting period: 
Medicine Daily 
Dose 
Route of 
administration & 
Vehicle – Adjuvant 
Date Diagnosis for 
which medicine 
taken 
 
 
  Starting Stopped  
Siddha 
 
     
Any other 
system of 
medicines 
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1. Brief details of the Siddha Medicine which seems to be toxic: 
Details Drug – 1 Drug – 2 Drug – 3 
a)Name of the medicine    
b)Manufacturing unit and 
batch No. And date 
   
c)Expiry date    
d)Purchased and obtained 
from 
   
e) composition of the 
formulation / part of the 
drug used 
   
 
b) Dietary Restrictions if any 
c) Whether the drug is consumed under Institutionally qualified medical supervision or 
used as self medication. 
d) Any other relevant information. 
5. Treatment provided for adverse reations: 
 
Recovered: 
 
 
 
 
 
Not Recovered: 
Unknown: 
 
 
 
Fatal: 
 
 
 
 
If Fatal 
 
Date  of death: 
 
Severe : Yes/ No. 
 
 
 
 
 
 
 
Reaction abated after drug stopped or dose 
reduced: 
 
 
Reaction reappeared after re introduction: 
Was the patient admitted to 
hospital? 
If yes, give name and address of 
Hospital 
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7. Any laboratory investigations done to evaluate other possibilities? If Yes specifiy: 
 
8. Whether the patient is suffering with any chronic disorders? 
Hepatic Renal Cardiac Diabetes Malnutrition 
 
Any other 
 
9. H/O previous allergies / Drug reactions: 
 
10.  Other illness (please describe): 
      This filled – in ADR report may be sent within one month of observation /   
occurrence of ADR 
 
 
Date : 
Station: 
 
Signature of the Investigator: 
 
Signature of the Lecturer:                   Signature of HOD 
  
Who can Report? 
                                         
                                   = Any Health care professional like Siddha Doctors/ 
                                   Nurses / siddha pharmacists / Patients etc. 
  Who to Report? 
                                  =All reactions, Drug interactions. 
 
Confidentiality? 
                                 =  The paient’s identity will be held in strict  confidence  
                                        And protected to the fullest extent. 
                                  = Submission of report will be taken up for remedial 
                                      Measures only not for legal claim 
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Complication adverse reactions if any  : Yes/ No 
 
Exacerbation of symptoms    : Yes/ No 
 
Patient not willing to continue   : 
 
Date:      Signature of the principal investigator 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI- 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRE CLINICAL AND CLINICAL ASSESSMENT AND EVALUATION OF 
 BAALAVAATHAM (PARESIS) WITH SIDDHA THERAPEUTIC 
MANAGEMENT IN CHILDREN 
 
FORM X DIETARY ADVICE FORM 
 
       1. S.I. No      :  2. OP/IP No:   3. Name: 
4. Age           :  5. Gender    :   6. Date of Enrolment: 
7. Informant:  8 . Reliability: 
 
THINGS TO TAKE 
 Increased intake of omega 4 fatty acid 
 Increase intake of vitamins and minerals 
 Intake of almond milk 
 A natural food as organic which is easily digestible and absorbed 
 
THINGS TO AVOID 
 Gluten like wheat be avoid 
 Casein like dairy products, yoghurts and soy should be avoided 
 Avoid junk food, pasta pizza burger and artificial food items etc.... 
 Avoid broiler chicken and white sugar 
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PDF of Trial
CTRI Website URL - http://ctri.nic.in
Clinical Trial Details (PDF Generation Date :- Sat, 07 Jul 2018 10:23:52 GMT)
 
CTRI Number CTRI/2018/04/013296 [Registered on: 16/04/2018] - Trial Registered Retrospectively
Last Modified On 13/04/2018
Post Graduate Thesis Yes
Type of Trial Interventional
Type of Study Drug
Siddha
Study Design Randomized, Parallel Group Trial
Public Title of Study Baalavatham (Paresis)- Siddha Thearapeutic management in Children
Scientific Title of
Study
Preclinical and Clinical Assessment and Evaluavtion of Baalavatham (Paresis) with Siddha
Thearapeutic management in Children
Secondary IDs if Any Secondary ID Identifier
Nil NIL
Details of Principal
Investigator or overall
Trial Coordinator
(multi-center study)
Details of Principal Investigator
Name G Ridhambara devi
Designation PG scholar
Affiliation National institute of siddha
Address Department of kuzhanthai maruthuvam National institute of siddha
Kancheepuram Department of kuzhanthai maruthuvam National
institute of siddha Kancheepuram
Kancheepuram
TAMIL NADU
600047
India
Phone 7708738987
Fax
Email ridhambara15@gmail.com
Details Contact
Person (Scientific
Query)
Details Contact Person (Scientific Query)
Name Dr M Meenakshi sundaram
Designation Head of the Department
Affiliation National Institute of siddha
Address Department of kuzhanthai maruthuvam National institute of siddha
Kancheepuram Department of kuzhanthai maruthuvam National
institute of siddha Kancheepuram
Kancheepuram
TAMIL NADU
600047
India
Phone 9444214582
Fax
Email mmssiddha@rediffmail.com
Details Contact
Person (Public Query)
Details Contact Person (Public Query)
Name G Ridhambara devi
Designation PG scholar
Affiliation National institute of siddha
Address Department of kuzhanthai maruthuvam National institute of siddha
Kancheepuram Department of kuzhanthai maruthuvam National
institute of siddha Kancheepuram
Kancheepuram
TAMIL NADU
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CTRI Website URL - http://ctri.nic.in
600047
India
Phone 7708738987
Fax
Email ridhambara15@gmail.com
Source of Monetary or
Material Support
Source of Monetary or Material Support
> Ayothidass pandithar hospital National institue of siddha kancheepuram chennai 47
Primary Sponsor Primary Sponsor Details
Name Ayothidoss pandithar hospital
Address Room no 4 Department of Kuzhanthai Maruthuvam National Institute
of siddha kancheepuram
Type of Sponsor Research institution and hospital
Details of Secondary
Sponsor
Name Address
Ayothidass pandithar hospital Room no 4 Department of Kuzhanthai
Maruthuvam National Institute of siddha
kancheepuram
Countries of
Recruitment
List of Countries
India
Sites of Study Name of Principal
Investigator 
Name of Site Site Address Phone/Fax/Email
G Ridhambara devi National institute of
siddha
Room no 4 Department
of kuzhanthai
maruthuvam National
institute of siddha
kancheepuram
Kancheepuram
TAMIL NADU
7708738987
ridhambara15@gmail.c
om
Details of Ethics
Committee
Name of Committee Approval Status Date of Approval Is Independent Ethics
Committee?
Institutional ethical
committee
Approved 14/10/2016 No
Regulatory Clearance
Status from DCGI
Status Date
Not Applicable No Date Specified
Health Condition /
Problems Studied
Health Type Condition
Patients Baalavaatham
Intervention /
Comparator Agent
Type Name Details
Intervention CHITRA MUTTI KUDINEER
Baala vaatha thylam
Chitra mutti kudineer 5 to
15mltwice a day with palm
jaggery for 45days Baalavaatha
thylam external
Comparator Agent not applicable not applicable
Inclusion Criteria Inclusion Criteria
Age From 2.00 Year(s)
Age To 12.00 Year(s)
Gender Both
Details Mono di tetra quadri paresis
weakness of one or more limb
loss of power and tone in muscles of the affected limb
difficulty inability in using the affected limb against gravity and
resistance
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CTRI Website URL - http://ctri.nic.in
difficulty in using the upper limb
Exclusion Criteria Exclusion Criteria
Details epilepsy
severe aggressiveness with ADHD
autism
cerebral palsy
congenital heart disease
any other serious illness
Method of Generating
Random Sequence
Not Applicable
Method of
Concealment
Not Applicable
Blinding/Masking Not Applicable
Primary Outcome Outcome Timepoints
to reduce the muscle spastisity to reduce the muscle spasticity
Secondary Outcome Outcome Timepoints
spasticity assessment
Range of motion assesment with goniometery
to reduce the muscle spasticity
Target Sample Size Total Sample Size=30
Sample Size from India=30
Phase of Trial Phase 4
Date of First
Enrollment (India)
18/08/2017
Date of First
Enrollment (Global)
No Date Specified
Estimated Duration of
Trial
Years=1
Months=6
Days=28
Recruitment Status of
Trial (Global)
Not Applicable
Recruitment Status of
Trial (India)
Open to Recruitment
Publication Details not yet
Brief Summary It is a single non randamized open and label trial to determine the  therapeutic management of
baalavaatham in children with inclusion criteria of age between 2 to 12 both sex Mono or di or tetra
or quadri paresis weakness of one or more limb, loss of power and tone in muscle of the affected
limb, difficulty or inability in using the affected limb against gravity and resistant, difficulty in using
the affected limb, this is treated with internal medicine chitra mutti kudineer at a dose of 5 to 15ml
twice a day with palm jaggery for 45 days and external theraphy thokkanam  with the medicated oil
baala vaatha thylam during the study period all the study related data will be recorded and
documented in a seperate trial master file for each patient during the trial period if any adverse
effect will be noticed and referred to pharmacovigilance department and further management will
also be given in NIS opd and ipd the entire trial will moniter by the research monitoring committee of
NIS during this trial all the safty and efficacy parameters will be recorded in the CRF after the
completion of trial all the study related data will be analysed statistically the outcome of trial will be
published in indian journal of medical research     
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